PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
13844001-0	1959	[On the therapy of depressive states with hypericin (Preliminary results with the experimental preparation Hyp.	hypericin	42-51	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	107-110
33723162-0	2021	Hypericin induces apoptosis in K562 cells via downregulation of Myc and Mdm2.	hypericin	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	64-67
34038765-2	2021	This review presents the primary biological results obtained with hypericin in photodynamic therapy applications, such as photodynamic cancer treatment, photoinactivation of microorganisms (PDI), tissue scarring, and photo diagnosis.	hypericin	66-75	peptidyl arginine deiminase 1	Homo sapiens	190-193
33556646-11	2021	Our findings indicate that hypericin possessed inhibition activity, and both rutin and cyanidin-3-O-glucoside resulted in a concentration-dependent inhibition of the PLpro, with activity in the micromolar range.	hypericin	27-36	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	166-171
33418948-8	2021	Hypericin-mediated photo-oxidative ER damage reduced the expression of miRNAs belonging to the miR-17-92 cluster in wild-type but not in PERK-deficient cells.	hypericin	0-9	miR-17-92a-1 cluster host gene	Homo sapiens	95-104
33418948-8	2021	Hypericin-mediated photo-oxidative ER damage reduced the expression of miRNAs belonging to the miR-17-92 cluster in wild-type but not in PERK-deficient cells.	hypericin	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	137-141
33723162-0	2021	Hypericin induces apoptosis in K562 cells via downregulation of Myc and Mdm2.	hypericin	0-9	MDM2 proto-oncogene	Homo sapiens	72-76
33723162-9	2021	Furthermore, after 24 h of exposure to hypericin with IC50 concentration, the expression of P53 and Bax genes increased and the expression of the Bcl2, Myc, and Mdm2 gene decreased.	hypericin	39-48	tumor protein p53	Homo sapiens	92-95
33723162-9	2021	Furthermore, after 24 h of exposure to hypericin with IC50 concentration, the expression of P53 and Bax genes increased and the expression of the Bcl2, Myc, and Mdm2 gene decreased.	hypericin	39-48	BCL2 associated X, apoptosis regulator	Homo sapiens	100-103
33723162-9	2021	Furthermore, after 24 h of exposure to hypericin with IC50 concentration, the expression of P53 and Bax genes increased and the expression of the Bcl2, Myc, and Mdm2 gene decreased.	hypericin	39-48	BCL2 apoptosis regulator	Homo sapiens	146-150
33723162-9	2021	Furthermore, after 24 h of exposure to hypericin with IC50 concentration, the expression of P53 and Bax genes increased and the expression of the Bcl2, Myc, and Mdm2 gene decreased.	hypericin	39-48	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	152-155
33723162-9	2021	Furthermore, after 24 h of exposure to hypericin with IC50 concentration, the expression of P53 and Bax genes increased and the expression of the Bcl2, Myc, and Mdm2 gene decreased.	hypericin	39-48	MDM2 proto-oncogene	Homo sapiens	161-165
33723162-10	2021	Conclusion: The results showed that hypericin exerts its cytotoxicity on K562 cancer cells by downregulating Mdm2 and Myc.	hypericin	36-45	MDM2 proto-oncogene	Homo sapiens	109-113
33723162-10	2021	Conclusion: The results showed that hypericin exerts its cytotoxicity on K562 cancer cells by downregulating Mdm2 and Myc.	hypericin	36-45	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-121
33364229-14	2020	Further, our findings indicate that in particular hypericin, rutin, and cyanidin-3-O-glucoside, represent suitable candidates for subsequent evaluation as PLpro inhibitors.	hypericin	50-59	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	155-160
33143088-5	2020	Hindrance of inflammatory cytokine signaling is likely dependent on the hyperforin content of SJW extract, but recent data reveal that hypericin can also exert relevant protective effects, mediated by activation of the cyclic adenosine monophosphate (cAMP)/protein kinase cAMP-dependent (PKA)/adenosine monophosphate activated protein kinase (AMPK) pathway, against high-fat-diet-induced metabolic abnormalities.	hypericin	135-144	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	343-347
33137690-7	2020	Molecular dynamics simulations demonstrated that hypericin (DeltaG = -18.6 and -19.3 kcal/mol), cyanidin-3-O-glucoside (DeltaG = -50.8 and -42.1 kcal/mol), and SRT2104 (DeltaG = -8.7 and -20.6 kcal/mol), formed stable interactions with the Mpro active site.	hypericin	49-58	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	240-244
33137690-8	2020	An enzyme-linked immunosorbent assay indicated that, albeit, not as potent as the covalent positive control (GC376), our leads inhibited the Mpro with activity in the micromolar range, and an order of effectiveness of hypericin and cyanidin-3-O-glucoside > SRT2104 > SRT1720.	hypericin	218-227	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	141-145
32718290-6	2021	RESULTS: In this study, we found that, treatment with hypericin (10 and 50 mg/kg) significantly suppresses expression of hippocampal interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- alpha) in maternal separation rat model.	hypericin	54-63	interleukin 6	Rattus norvegicus	133-146
32298799-8	2020	Our results showed that a synergistic combination of photoactive hypericin and Manumycin A decreased viability, inhibited both short- and long-term cell proliferation, decreased levels of IAPs proteins (cIAP1, cIAP2, XIAP and survivin), induced an apoptotic PARP cleavage associated with decline in procaspase-3 level, promoted phagocytosis of cancer cells, and restored chemosensitivity to oxaliplatin.	hypericin	65-74	baculoviral IAP repeat containing 2	Homo sapiens	203-208
32298799-8	2020	Our results showed that a synergistic combination of photoactive hypericin and Manumycin A decreased viability, inhibited both short- and long-term cell proliferation, decreased levels of IAPs proteins (cIAP1, cIAP2, XIAP and survivin), induced an apoptotic PARP cleavage associated with decline in procaspase-3 level, promoted phagocytosis of cancer cells, and restored chemosensitivity to oxaliplatin.	hypericin	65-74	baculoviral IAP repeat containing 3	Homo sapiens	210-215
32298799-8	2020	Our results showed that a synergistic combination of photoactive hypericin and Manumycin A decreased viability, inhibited both short- and long-term cell proliferation, decreased levels of IAPs proteins (cIAP1, cIAP2, XIAP and survivin), induced an apoptotic PARP cleavage associated with decline in procaspase-3 level, promoted phagocytosis of cancer cells, and restored chemosensitivity to oxaliplatin.	hypericin	65-74	X-linked inhibitor of apoptosis	Homo sapiens	217-221
32298799-8	2020	Our results showed that a synergistic combination of photoactive hypericin and Manumycin A decreased viability, inhibited both short- and long-term cell proliferation, decreased levels of IAPs proteins (cIAP1, cIAP2, XIAP and survivin), induced an apoptotic PARP cleavage associated with decline in procaspase-3 level, promoted phagocytosis of cancer cells, and restored chemosensitivity to oxaliplatin.	hypericin	65-74	collagen type XI alpha 2 chain	Homo sapiens	258-262
32298799-8	2020	Our results showed that a synergistic combination of photoactive hypericin and Manumycin A decreased viability, inhibited both short- and long-term cell proliferation, decreased levels of IAPs proteins (cIAP1, cIAP2, XIAP and survivin), induced an apoptotic PARP cleavage associated with decline in procaspase-3 level, promoted phagocytosis of cancer cells, and restored chemosensitivity to oxaliplatin.	hypericin	65-74	caspase 3	Homo sapiens	299-311
32497635-2	2020	In this study we aimed to evaluate the efficacy of hypericin (HYP) encapsulated on Pluronic  P123 (HYP/P123) photodynamic therapy (PDT) in a comprehensive panel of human cervical cancer-derived cell lines, including HeLa (HPV 18-positive), SiHa (HPV 16-positive), CaSki (HPV 16 and 18-positive), and C33A (HPV-negative), compared to a nontumorigenic human epithelial cell line (HaCaT).	hypericin	51-60	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	62-65
32497635-2	2020	In this study we aimed to evaluate the efficacy of hypericin (HYP) encapsulated on Pluronic  P123 (HYP/P123) photodynamic therapy (PDT) in a comprehensive panel of human cervical cancer-derived cell lines, including HeLa (HPV 18-positive), SiHa (HPV 16-positive), CaSki (HPV 16 and 18-positive), and C33A (HPV-negative), compared to a nontumorigenic human epithelial cell line (HaCaT).	hypericin	51-60	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	99-107
32718290-6	2021	RESULTS: In this study, we found that, treatment with hypericin (10 and 50 mg/kg) significantly suppresses expression of hippocampal interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- alpha) in maternal separation rat model.	hypericin	54-63	interleukin 6	Rattus norvegicus	148-152
32718290-6	2021	RESULTS: In this study, we found that, treatment with hypericin (10 and 50 mg/kg) significantly suppresses expression of hippocampal interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- alpha) in maternal separation rat model.	hypericin	54-63	tumor necrosis factor	Rattus norvegicus	158-185
32718290-6	2021	RESULTS: In this study, we found that, treatment with hypericin (10 and 50 mg/kg) significantly suppresses expression of hippocampal interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- alpha) in maternal separation rat model.	hypericin	54-63	tumor necrosis factor	Rattus norvegicus	187-197
33680035-9	2020	Real-time PCR showed that expression level of Bax, p53 and Bax genes increases and Bcl2 gene decreases in AGS cell lines after treatment by hypericin.	hypericin	140-149	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
33680035-9	2020	Real-time PCR showed that expression level of Bax, p53 and Bax genes increases and Bcl2 gene decreases in AGS cell lines after treatment by hypericin.	hypericin	140-149	tumor protein p53	Homo sapiens	51-54
33680035-9	2020	Real-time PCR showed that expression level of Bax, p53 and Bax genes increases and Bcl2 gene decreases in AGS cell lines after treatment by hypericin.	hypericin	140-149	BCL2 associated X, apoptosis regulator	Homo sapiens	59-62
33680035-9	2020	Real-time PCR showed that expression level of Bax, p53 and Bax genes increases and Bcl2 gene decreases in AGS cell lines after treatment by hypericin.	hypericin	140-149	BCL2 apoptosis regulator	Homo sapiens	83-87
31430575-0	2019	Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels.	hypericin	14-23	BCL2 apoptosis regulator	Homo sapiens	24-28
33463265-0	2020	Hypericin-Loaded Transferrin Nanoparticles Induce PP2A-Regulated BMI1 Degradation in Colorectal Cancer-Specific Chemo-Photodynamic Therapy.	hypericin	0-9	transferrin	Homo sapiens	17-28
33463265-0	2020	Hypericin-Loaded Transferrin Nanoparticles Induce PP2A-Regulated BMI1 Degradation in Colorectal Cancer-Specific Chemo-Photodynamic Therapy.	hypericin	0-9	protein phosphatase 2 phosphatase activator	Homo sapiens	50-54
33463265-0	2020	Hypericin-Loaded Transferrin Nanoparticles Induce PP2A-Regulated BMI1 Degradation in Colorectal Cancer-Specific Chemo-Photodynamic Therapy.	hypericin	0-9	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	65-69
33463265-5	2020	We have synthesized hypericin-loaded transferrin nanoformulations (HTfNPs) overcoming the compromised hydrophobicity and poor bioavailability of the placebo drug.	hypericin	20-29	transferrin	Homo sapiens	37-48
33463265-6	2020	Targeted PDT with hypericin nanocomposite-induced BMI1 degradation assisted CRC retardation.	hypericin	18-27	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	50-54
33463265-7	2020	In the present study, transferrin nanoparticles were reported to control the premature release of hypericin and improve its availability with better targeting at the disease site.	hypericin	98-107	transferrin	Homo sapiens	22-33
30387402-4	2020	Following our previous work regarding to the properties of the Pluronics with different photosensitizer (PS) for photodynamic therapy (PDT), in this study we aimed to evaluate the efficacy of supersaturated hypericin (HYP) encapsulated on Pluronic  P123 (HYP/P123) against breast cancer cells (MCF-7) and non-tumorigenic breast cells (MCF-10A).	hypericin	207-216	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	218-221
30387402-4	2020	Following our previous work regarding to the properties of the Pluronics with different photosensitizer (PS) for photodynamic therapy (PDT), in this study we aimed to evaluate the efficacy of supersaturated hypericin (HYP) encapsulated on Pluronic  P123 (HYP/P123) against breast cancer cells (MCF-7) and non-tumorigenic breast cells (MCF-10A).	hypericin	207-216	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	255-263
32508149-0	2020	The Influence of Hypericin-Mediated Photodynamic Therapy on Interleukin-8 and -10 Secretion in Colon Cancer Cells.	hypericin	17-26	C-X-C motif chemokine ligand 8	Homo sapiens	60-81
32508149-1	2020	The aim of this study was to measure the secretion of interleukin (IL)-8 and -10 during an elicited immune response following sublethal doses of hypericin-mediated photodynamic therapy (HY-PDT) in experimental models of residual colon cancer cells in vitro.	hypericin	145-154	C-X-C motif chemokine ligand 8	Homo sapiens	54-80
31047931-8	2019	All these findings suggest that hypericin is a natural thrombin inhibitor with a unique dianthrone skeleton, which can be used as a good candidate to develop novel thrombin inhibitors with improved properties.	hypericin	32-41	coagulation factor II, thrombin	Homo sapiens	55-63
31047931-8	2019	All these findings suggest that hypericin is a natural thrombin inhibitor with a unique dianthrone skeleton, which can be used as a good candidate to develop novel thrombin inhibitors with improved properties.	hypericin	32-41	coagulation factor II, thrombin	Homo sapiens	164-172
30551474-0	2019	Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.	hypericin	49-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-32
31337977-0	2019	Hypericin maintians PDX1 expression via the Erk pathway and protects islet beta-cells against glucotoxicity and lipotoxicity.	hypericin	0-9	pancreatic and duodenal homeobox 1	Mus musculus	20-24
31337977-0	2019	Hypericin maintians PDX1 expression via the Erk pathway and protects islet beta-cells against glucotoxicity and lipotoxicity.	hypericin	0-9	mitogen-activated protein kinase 1	Mus musculus	44-47
31337977-5	2019	Then, we further demonstrated that hypericin elicited its protective effects against glucotoxicity and lipotoxicity in INS-1 cells by attenuating the reduction in pancreatic duodenal homeobox-1 (PDX1) expression and Erk activity.	hypericin	35-44	pancreatic and duodenal homeobox 1	Rattus norvegicus	195-199
31337977-5	2019	Then, we further demonstrated that hypericin elicited its protective effects against glucotoxicity and lipotoxicity in INS-1 cells by attenuating the reduction in pancreatic duodenal homeobox-1 (PDX1) expression and Erk activity.	hypericin	35-44	Eph receptor B1	Rattus norvegicus	216-219
30814492-0	2019	Author Correction: Hypericin-mediated sonodynamic therapy induces autophagy and decreases lipids in THP-1 macrophage by promoting ROS-dependent nuclear translocation of TFEB.	hypericin	19-28	GLI family zinc finger 2	Homo sapiens	100-105
30814492-0	2019	Author Correction: Hypericin-mediated sonodynamic therapy induces autophagy and decreases lipids in THP-1 macrophage by promoting ROS-dependent nuclear translocation of TFEB.	hypericin	19-28	transcription factor EB	Homo sapiens	169-173
30782173-8	2019	Western blot analyses revealed that hypericin-PDT treatment resulted in downregulation of Bcl-2 and enhanced the expression of Bad, cytochrome C, and AIF.	hypericin	36-45	BCL2 apoptosis regulator	Homo sapiens	90-95
30782173-8	2019	Western blot analyses revealed that hypericin-PDT treatment resulted in downregulation of Bcl-2 and enhanced the expression of Bad, cytochrome C, and AIF.	hypericin	36-45	cytochrome c, somatic	Homo sapiens	132-144
30782173-9	2019	Cleavage of caspases-3/-7/-9/-8, Bid, and PARP was increased in hypericin-PDT-treated ATL cells.	hypericin	64-73	BH3 interacting domain death agonist	Homo sapiens	33-36
30782173-9	2019	Cleavage of caspases-3/-7/-9/-8, Bid, and PARP was increased in hypericin-PDT-treated ATL cells.	hypericin	64-73	collagen type XI alpha 2 chain	Homo sapiens	42-46
30782173-10	2019	In a luciferase assay, hypericin-PDT treatment was able to activate the promoter activity of Bax and p53, resulting in enhanced expression of Bax and p53 proteins.	hypericin	23-32	BCL2 associated X, apoptosis regulator	Homo sapiens	93-96
30782173-10	2019	In a luciferase assay, hypericin-PDT treatment was able to activate the promoter activity of Bax and p53, resulting in enhanced expression of Bax and p53 proteins.	hypericin	23-32	tumor protein p53	Homo sapiens	101-104
30782173-10	2019	In a luciferase assay, hypericin-PDT treatment was able to activate the promoter activity of Bax and p53, resulting in enhanced expression of Bax and p53 proteins.	hypericin	23-32	BCL2 associated X, apoptosis regulator	Homo sapiens	142-145
30782173-10	2019	In a luciferase assay, hypericin-PDT treatment was able to activate the promoter activity of Bax and p53, resulting in enhanced expression of Bax and p53 proteins.	hypericin	23-32	tumor protein p53	Homo sapiens	150-153
30551474-0	2019	Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.	hypericin	88-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-32
30221528-12	2018	Moreover, after 24 hours of exposure to hypericin with MDA- MB-231 IC50 concentration, the expression of P53 and P21 genes upregulated in MDA-MB-175-VII much more than MDA-MB-231 when both cell lines were treated with 24 hours IC50 dose of MDA-MB-231.	hypericin	40-49	tumor protein p53	Homo sapiens	105-108
30221528-12	2018	Moreover, after 24 hours of exposure to hypericin with MDA- MB-231 IC50 concentration, the expression of P53 and P21 genes upregulated in MDA-MB-175-VII much more than MDA-MB-231 when both cell lines were treated with 24 hours IC50 dose of MDA-MB-231.	hypericin	40-49	H3 histone pseudogene 16	Homo sapiens	113-116
30221528-15	2018	Therefore, it is of great importance to consider that hypericin would have better impact on cells or tumors with wild type P53.	hypericin	54-63	tumor protein p53	Homo sapiens	123-126
30221528-13	2018	The ICC analysis on P21 confirmed that by treating both cell lines with MDA-MB-231 IC50 dose of hypericin for 24 hours, this protein is overexpressed much more in MDA-MB-175-VII cells.	hypericin	96-105	H3 histone pseudogene 16	Homo sapiens	20-23
30221528-14	2018	CONCLUSION: The results of this study demonstrated that hypericin"s apoptotic and cytotoxic effects on cancer cells may be mediated via P53 overexpression, cell cycle arrest and the subsequent apoptosis.	hypericin	56-65	tumor protein p53	Homo sapiens	136-139
29416737-0	2018	Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway.	hypericin	0-9	nuclear factor of activated T cells 1	Homo sapiens	84-90
30150427-0	2018	Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin.	hypericin	44-53	albumin	Homo sapiens	104-117
30150427-7	2018	Bovine serum albumin can serve as a transport protein for hypericin since the binding force between both molecules is adequate.	hypericin	58-67	albumin	Homo sapiens	7-20
30097118-10	2018	Hypericin reduced HO-1 and NS5A in a time- and dose- dependent manner.	hypericin	0-9	heme oxygenase 1	Homo sapiens	18-22
30097118-11	2018	Chidamide, but not 5-Aza-dc, restored hypericin-induced reduction in HCV NS3 expression and reversed HO-1 expression in Ava5 cells.	hypericin	38-47	KRAS proto-oncogene, GTPase	Homo sapiens	73-76
30097118-15	2018	CONCLUSION: In conclusion, hypericin inhibits HCV replication via down-regulation of HO-1 expression and deacetylation.	hypericin	27-36	heme oxygenase 1	Homo sapiens	85-89
29665654-0	2018	Hypericin affects cancer side populations via competitive inhibition of BCRP.	hypericin	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	72-76
29969677-0	2018	Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer.	hypericin	59-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	11-16
29969677-6	2018	The effect of ABCG2 inhibition, using 10 muM Ko143, on cytotoxicity following Hypericin-PDT was evaluated.	hypericin	78-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-19
29969677-9	2018	Inhibition of ABCG2 in spheroids with Ko143 resulted in an enhanced Hypericin-PDT effect compared to Hypericin-PDT alone (HT29: p = 0.04, HCT116: p = 0.01).	hypericin	68-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-19
29969677-9	2018	Inhibition of ABCG2 in spheroids with Ko143 resulted in an enhanced Hypericin-PDT effect compared to Hypericin-PDT alone (HT29: p = 0.04, HCT116: p = 0.01).	hypericin	101-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-19
29969677-10	2018	CONCLUSIONS: Hypericin-PDT has reduced efficacy in CRC spheroids as compared to 2D cultures, which may be attributable through upregulation in ABCG2.	hypericin	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	143-148
29969677-11	2018	The clinical efficacy of Hypericin-PDT may be enhanced by ABCG2 inhibition.	hypericin	25-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	58-63
29737376-0	2018	Author Correction: Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.	hypericin	19-28	heat shock protein family A (Hsp70) member 4	Homo sapiens	126-131
29737376-0	2018	Author Correction: Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.	hypericin	19-28	calreticulin	Homo sapiens	136-148
29416737-6	2018	The activity of hypericin on osteoclasts and breast cancer-mediated osteoclastogenesis was associated with the inhibition of NFATc1 signaling pathway and attenuation of Ca2+ oscillation.	hypericin	16-25	nuclear factor of activated T cells 1	Homo sapiens	125-131
27825966-0	2016	Hypericin inhibits oligomeric amyloid beta42-induced inflammation response in microglia and ameliorates cognitive deficits in an amyloid beta injection mouse model of Alzheimer"s disease by suppressing MKL1.	hypericin	0-9	myocardin related transcription factor A	Mus musculus	202-206
27158772-4	2017	It is known that both, ceramide and hypericin can significantly influence protein kinase C (PKC) activity.	hypericin	36-45	protein kinase C delta	Homo sapiens	92-95
27158772-5	2017	Western blotting analysis shows increase of PKCdelta autophosphorylation at Ser645 (p(S645)PKCdelta) in glioma cells incubated with 500 nM hypericin and confocal-fluorescence microscopy distinguishes p(S645)PKCdelta localization between GA related compartments and nucleus.	hypericin	139-148	protein kinase C delta	Homo sapiens	44-52
27158772-5	2017	Western blotting analysis shows increase of PKCdelta autophosphorylation at Ser645 (p(S645)PKCdelta) in glioma cells incubated with 500 nM hypericin and confocal-fluorescence microscopy distinguishes p(S645)PKCdelta localization between GA related compartments and nucleus.	hypericin	139-148	protein kinase C delta	Homo sapiens	91-99
27158772-5	2017	Western blotting analysis shows increase of PKCdelta autophosphorylation at Ser645 (p(S645)PKCdelta) in glioma cells incubated with 500 nM hypericin and confocal-fluorescence microscopy distinguishes p(S645)PKCdelta localization between GA related compartments and nucleus.	hypericin	139-148	protein kinase C delta	Homo sapiens	91-99
27158772-7	2017	Image processing based on conceptual qualitative description is combined with numerical treatment via simple exponential saturation model which describes redistribution of p(S645)PKCdelta between nucleus and GA related compartments after hypericin administration.	hypericin	238-247	protein kinase C delta	Homo sapiens	179-187
27923686-0	2017	Photoactivated hypericin increases the expression of SOD-2 and makes MCF-7 cells resistant to photodynamic therapy.	hypericin	15-24	superoxide dismutase 2	Homo sapiens	53-58
27923686-3	2017	The difference in the dynamics of reactive oxygen species after hypericin activation was related to increased activity of SOD-2 in MCF-7 cells compared to MDA-MB-231 cells.	hypericin	64-73	superoxide dismutase 2	Homo sapiens	122-127
27923686-4	2017	Indeed, photodynamic therapy with hypericin significantly increased SOD-2 activity in MCF-7 cells, but only slightly in MDA-MB-231 cells.	hypericin	34-43	superoxide dismutase 2	Homo sapiens	68-73
27923686-6	2017	The role of SOD-2 in the resistance of MCF-7 cells to photodynamic therapy with hypericin was monitored using SOD-2 inhibitor - 2-methoxyestradiol.	hypericin	80-89	superoxide dismutase 2	Homo sapiens	12-17
27923686-8	2017	Furthermore, methoxyestradiol potentiated the activation of caspase 3/7 and apoptosis induced by photodynamic therapy with hypericin.	hypericin	123-132	caspase 3	Homo sapiens	60-69
28237688-4	2017	We have studied the effect of hypericin on PKCdelta phosphorylation in U87 MG cells before and after light application.	hypericin	30-39	protein kinase C delta	Homo sapiens	43-51
28237688-5	2017	Hypericin increased PKCdelta phosphorylation at tyrosine 155 in the regulatory domain and serine 645 in the catalytic domain.	hypericin	0-9	protein kinase C delta	Homo sapiens	20-28
28237688-9	2017	After hypericin and light application, PKCdelta phosphorylated at a regulatory domain which is in the nucleus.	hypericin	6-15	protein kinase C delta	Homo sapiens	39-47
28373118-0	2017	Synergism between PKCdelta regulators hypericin and rottlerin enhances apoptosis in U87 MG glioma cells after light stimulation.	hypericin	38-47	protein kinase C delta	Homo sapiens	18-26
27302958-7	2017	Hypericin prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression.	hypericin	0-9	BCL2 apoptosis regulator	Homo sapiens	66-71
27302958-7	2017	Hypericin prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression.	hypericin	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	98-101
27302958-9	2017	Pretreatment with hypericin strongly inhibited the activation of MAPKs, including P38, JNK, and ERK1/2.	hypericin	18-27	mitogen-activated protein kinase 1	Homo sapiens	82-85
27302958-9	2017	Pretreatment with hypericin strongly inhibited the activation of MAPKs, including P38, JNK, and ERK1/2.	hypericin	18-27	mitogen-activated protein kinase 8	Homo sapiens	87-90
27302958-9	2017	Pretreatment with hypericin strongly inhibited the activation of MAPKs, including P38, JNK, and ERK1/2.	hypericin	18-27	mitogen-activated protein kinase 3	Homo sapiens	96-102
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	interleukin 1 alpha	Mus musculus	143-151
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	interleukin 6	Mus musculus	154-167
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	interleukin 6	Mus musculus	169-173
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	tumor necrosis factor	Mus musculus	176-203
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	tumor necrosis factor	Mus musculus	205-214
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	nitric oxide synthase 2, inducible	Mus musculus	220-251
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	nitric oxide synthase 2, inducible	Mus musculus	253-257
27825966-5	2016	We further found that hypericin ameliorates inflammatory response by suppressing MKL1, which is the essential cofactor of p65 during the transcription process.	hypericin	22-31	myocardin related transcription factor A	Mus musculus	81-85
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	interleukin 1 beta	Mus musculus	124-141
27825966-5	2016	We further found that hypericin ameliorates inflammatory response by suppressing MKL1, which is the essential cofactor of p65 during the transcription process.	hypericin	22-31	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	122-125
27314518-6	2016	In the present work, we focused on Hypericin (Hyp) and HypPDT effects on the cell viability, oxidative stress, and the distribution of Bcl2 family members in human coronary artery endothelial (HCAEC) cells.	hypericin	35-44	BCL2 apoptosis regulator	Homo sapiens	135-139
27261575-0	2016	Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.	hypericin	54-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
26673286-6	2015	Importantly, we have also discovered that photoactivated hypericin induced apoptosis by activating the mitochondrial caspase pathway and inhibiting the activation of the vascular endothelial growth factor-A (VEGF-A)-mediated PI3K/Akt pathway.	hypericin	57-66	vascular endothelial growth factor A	Homo sapiens	170-206
26612349-6	2016	Moreover, hypericin seems to induce CYP1A2 in HepG2 cells and to inhibit its expression in HepaRG cells while hyperforin induced CYP1A2 in HepG2 and in WRL-68 cells.	hypericin	10-19	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	36-42
26612349-7	2016	Additionally, hypericin and hyperforin induce CYP2D6 in HepG2 cells but inhibits its expression in HepaRG and in WRL-68 cells.	hypericin	14-23	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
27241169-8	2016	Combined treatment with hypericin and YM155 led to a more severe dissipation of the mitochondrial membrane potential and caused an increase in caspase-3 activation and subsequent PARP cleavage.	hypericin	24-33	caspase 3	Homo sapiens	143-152
27241169-8	2016	Combined treatment with hypericin and YM155 led to a more severe dissipation of the mitochondrial membrane potential and caused an increase in caspase-3 activation and subsequent PARP cleavage.	hypericin	24-33	poly(ADP-ribose) polymerase 1	Homo sapiens	179-183
26940808-6	2016	Molecular docking models showed that hypericin has the strongest affinity to P-glycoprotein involved in the cell detoxification.	hypericin	37-46	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
26940808-7	2016	Presence of 10 muM quinizarin, emodin or hypericin increased P-glycoprotein function in U87 MG cells.	hypericin	41-50	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
26673286-6	2015	Importantly, we have also discovered that photoactivated hypericin induced apoptosis by activating the mitochondrial caspase pathway and inhibiting the activation of the vascular endothelial growth factor-A (VEGF-A)-mediated PI3K/Akt pathway.	hypericin	57-66	vascular endothelial growth factor A	Homo sapiens	208-214
26673286-6	2015	Importantly, we have also discovered that photoactivated hypericin induced apoptosis by activating the mitochondrial caspase pathway and inhibiting the activation of the vascular endothelial growth factor-A (VEGF-A)-mediated PI3K/Akt pathway.	hypericin	57-66	AKT serine/threonine kinase 1	Homo sapiens	230-233
25222735-12	2015	It was possible to identify additionally two carcinoma in situ, eight pTa, and one pT1 lesions with PVP-hypericin and blue light.	hypericin	104-113	zinc finger protein 77	Homo sapiens	83-86
26330116-0	2015	Hypericin-mediated photodynamic therapy induces apoptosis in K562 human leukemia cells through JNK pathway modulation.	hypericin	0-9	mitogen-activated protein kinase 8	Homo sapiens	95-98
24510318-0	2015	Alterations in dysadherin expression and F-actin reorganization: a possible mechanism of hypericin-mediated photodynamic therapy in colon adenocarcinoma cells.	hypericin	89-98	FXYD domain containing ion transport regulator 5	Homo sapiens	15-25
26182357-0	2015	Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.	hypericin	19-28	mitogen-activated protein kinase 8	Rattus norvegicus	101-104
26182357-0	2015	Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.	hypericin	19-28	Eph receptor B1	Rattus norvegicus	105-108
26182357-0	2015	Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.	hypericin	19-28	caspase 9	Rattus norvegicus	142-151
26182357-0	2015	Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.	hypericin	19-28	caspase 3	Rattus norvegicus	152-161
26182357-0	2015	Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.	hypericin	19-28	BCL2 associated X, apoptosis regulator	Rattus norvegicus	175-178
26182357-0	2015	Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.	hypericin	19-28	BCL2, apoptosis regulator	Rattus norvegicus	182-187
26182357-9	2015	Photoactivated hypericin triggered apoptosis through activation of caspase-3 and caspase-9 and elevation of the Bax-to B-cell lymphoma 2 (Bcl-2) ratio.	hypericin	15-24	caspase 3	Rattus norvegicus	67-76
26182357-9	2015	Photoactivated hypericin triggered apoptosis through activation of caspase-3 and caspase-9 and elevation of the Bax-to B-cell lymphoma 2 (Bcl-2) ratio.	hypericin	15-24	caspase 9	Rattus norvegicus	81-90
26182357-9	2015	Photoactivated hypericin triggered apoptosis through activation of caspase-3 and caspase-9 and elevation of the Bax-to B-cell lymphoma 2 (Bcl-2) ratio.	hypericin	15-24	BCL2 associated X, apoptosis regulator	Rattus norvegicus	112-115
26182357-9	2015	Photoactivated hypericin triggered apoptosis through activation of caspase-3 and caspase-9 and elevation of the Bax-to B-cell lymphoma 2 (Bcl-2) ratio.	hypericin	15-24	BCL2, apoptosis regulator	Rattus norvegicus	119-136
26182357-9	2015	Photoactivated hypericin triggered apoptosis through activation of caspase-3 and caspase-9 and elevation of the Bax-to B-cell lymphoma 2 (Bcl-2) ratio.	hypericin	15-24	BCL2, apoptosis regulator	Rattus norvegicus	138-143
24994473-3	2014	However, as previously demonstrated by our group, hypericin induces the expression of two ABC transporters: multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).	hypericin	50-59	ATP binding cassette subfamily C member 1	Homo sapiens	108-149
26074732-11	2015	The mitochondria membrane potential in SP2/0 cells was decreased significantly after incubated with the 0.025 muM and 0.5 muM hypericin (P < 0.05).	hypericin	126-135	Sp2 transcription factor	Mus musculus	39-42
25653524-0	2015	The efficacy and mechanism of apoptosis induction by hypericin-mediated sonodynamic therapy in THP-1 macrophages.	hypericin	53-62	GLI family zinc finger 2	Homo sapiens	95-100
25300800-0	2014	Effect of PKCalpha expression on Bcl-2 phosphorylation and cell death by hypericin.	hypericin	73-82	protein kinase C alpha	Homo sapiens	10-18
25300800-0	2014	Effect of PKCalpha expression on Bcl-2 phosphorylation and cell death by hypericin.	hypericin	73-82	BCL2 apoptosis regulator	Homo sapiens	33-38
25300800-1	2014	In order to explain the contribution of the protein kinase Calpha (PKCalpha) in apoptosis induced by photo-activation of hypericin (Hyp), a small interfering RNA was used for post-transcriptional silencing of pkcalpha gene expression.	hypericin	121-130	protein kinase C alpha	Homo sapiens	44-65
25300800-1	2014	In order to explain the contribution of the protein kinase Calpha (PKCalpha) in apoptosis induced by photo-activation of hypericin (Hyp), a small interfering RNA was used for post-transcriptional silencing of pkcalpha gene expression.	hypericin	121-130	protein kinase C alpha	Homo sapiens	67-75
25300800-1	2014	In order to explain the contribution of the protein kinase Calpha (PKCalpha) in apoptosis induced by photo-activation of hypericin (Hyp), a small interfering RNA was used for post-transcriptional silencing of pkcalpha gene expression.	hypericin	121-130	protein kinase C alpha	Homo sapiens	209-217
24994473-3	2014	However, as previously demonstrated by our group, hypericin induces the expression of two ABC transporters: multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).	hypericin	50-59	ATP binding cassette subfamily C member 1	Homo sapiens	151-155
24994473-3	2014	However, as previously demonstrated by our group, hypericin induces the expression of two ABC transporters: multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).	hypericin	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	161-193
24994473-3	2014	However, as previously demonstrated by our group, hypericin induces the expression of two ABC transporters: multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).	hypericin	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	195-199
24994473-9	2014	Nevertheless, hypericin did increase the expression of MRP1 transporter in A2780 and A2780cis cells indicating the impact of hypericin on certain resistance mechanisms.	hypericin	14-23	ATP binding cassette subfamily C member 1	Homo sapiens	55-59
24994473-9	2014	Nevertheless, hypericin did increase the expression of MRP1 transporter in A2780 and A2780cis cells indicating the impact of hypericin on certain resistance mechanisms.	hypericin	125-134	ATP binding cassette subfamily C member 1	Homo sapiens	55-59
24994473-10	2014	Additionally, our results indicate that hypericin may be the potential substrate of BCRP transporter.	hypericin	40-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-88
24994473-12	2014	Thus, hypericin represents another SJW metabolite that might be able to affect the effectiveness of anti-cancer drugs and that could interact with ABC transporters, particularly with BCRP.	hypericin	6-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	183-187
24950468-0	2014	Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway.	hypericin	0-9	mitogen-activated protein kinase 1	Mus musculus	94-97
24950468-4	2014	HP inhibited RANKL-induced osteoclast differentiation in bone marrow macrophages (BMMs) and RAW264.7 cell line without any evidence of cytotoxicity.	hypericin	0-2	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	13-18
24950468-7	2014	We thus examined the molecular mechanism and showed that HP significantly inhibited the ERK/mitogen-activated protein kinase (MAPK) signalling pathway without affecting nuclear factor kappaB (NF-kappaB), c-Jun N-terminal kinase (JNK) and p38 signalling in RANKL-stimulated BMMs.	hypericin	57-59	mitogen-activated protein kinase 14	Mus musculus	238-241
24950468-7	2014	We thus examined the molecular mechanism and showed that HP significantly inhibited the ERK/mitogen-activated protein kinase (MAPK) signalling pathway without affecting nuclear factor kappaB (NF-kappaB), c-Jun N-terminal kinase (JNK) and p38 signalling in RANKL-stimulated BMMs.	hypericin	57-59	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	256-261
24950468-6	2014	As HP has been previously reported to inhibit signalling pathway such as ERK and NF-kappaB in other cells, which is also important in osteoclast differentiation.	hypericin	3-5	mitogen-activated protein kinase 1	Mus musculus	73-76
24950468-9	2014	Taken together, the results suggest that HP inhibits RANKL-mediated osteoclastogenesis via affecting ERK signalling in vitro and suppresses wear particle-induced osteolysis in vivo.	hypericin	41-43	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	53-58
24950468-7	2014	We thus examined the molecular mechanism and showed that HP significantly inhibited the ERK/mitogen-activated protein kinase (MAPK) signalling pathway without affecting nuclear factor kappaB (NF-kappaB), c-Jun N-terminal kinase (JNK) and p38 signalling in RANKL-stimulated BMMs.	hypericin	57-59	mitogen-activated protein kinase 1	Mus musculus	88-91
24950468-9	2014	Taken together, the results suggest that HP inhibits RANKL-mediated osteoclastogenesis via affecting ERK signalling in vitro and suppresses wear particle-induced osteolysis in vivo.	hypericin	41-43	mitogen-activated protein kinase 1	Mus musculus	101-104
24950468-7	2014	We thus examined the molecular mechanism and showed that HP significantly inhibited the ERK/mitogen-activated protein kinase (MAPK) signalling pathway without affecting nuclear factor kappaB (NF-kappaB), c-Jun N-terminal kinase (JNK) and p38 signalling in RANKL-stimulated BMMs.	hypericin	57-59	mitogen-activated protein kinase 1	Mus musculus	126-130
24950468-7	2014	We thus examined the molecular mechanism and showed that HP significantly inhibited the ERK/mitogen-activated protein kinase (MAPK) signalling pathway without affecting nuclear factor kappaB (NF-kappaB), c-Jun N-terminal kinase (JNK) and p38 signalling in RANKL-stimulated BMMs.	hypericin	57-59	mitogen-activated protein kinase 8	Mus musculus	229-232
25076130-11	2014	However, hypericin-PDT was effective in killing both unpigmented (A375 and 501mel) and pigmented (UCT Mel-1) melanoma cells by specific mechanisms involving the externalization of phosphatidylserines, cell shrinkage and loss of cell membrane integrity.	hypericin	9-18	PR/SET domain 16	Homo sapiens	102-107
24066060-5	2013	We focused on the redox perylene-quinone Hypericin (HYP) and showed that HYP targets Hsp90 for polyubiquitination, degradation and inactivation.	hypericin	41-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	85-90
25261644-0	2014	The effects of hypericin on ADAMTS and p53 gene expression in MCF-7 breast cancer cells.	hypericin	15-24	tumor protein p53	Homo sapiens	39-42
25261644-1	2014	PURPOSE: The purpose of this study was to determine the effects of hypericin on MCF-7 (Michigan Cancer Foundation- 7) breast cancer cells, as it is known to exert an antitumor effect on the expression and regulation of ADAMTS1, 3, 10 and the p53 gene in breast cancer cells.	hypericin	67-76	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	219-226
25261644-1	2014	PURPOSE: The purpose of this study was to determine the effects of hypericin on MCF-7 (Michigan Cancer Foundation- 7) breast cancer cells, as it is known to exert an antitumor effect on the expression and regulation of ADAMTS1, 3, 10 and the p53 gene in breast cancer cells.	hypericin	67-76	tumor protein p53	Homo sapiens	242-245
25261644-5	2014	RESULTS: While the expression of ADAMTS1 in MFC-7 cells decreased to 0.04-fold after exposure to 1 mug /mL hypericin, the expression increased by 5.6- and 36-fold with 5 and 7.5 mug/mL, respectively.	hypericin	107-116	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	33-40
25261644-6	2014	Furthermore, ADAMTS3 expression in MCF7 cells increased 3.9-fold with the use of 5 mug /mL of hypericin.	hypericin	94-103	ADAM metallopeptidase with thrombospondin type 1 motif 3	Homo sapiens	13-20
25261644-10	2014	Hypericin may therefore exert its antitumor and apoptotic effects in MFC-7 cells via ADAMTS1 and ADAMTS3.	hypericin	0-9	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	85-92
25261644-10	2014	Hypericin may therefore exert its antitumor and apoptotic effects in MFC-7 cells via ADAMTS1 and ADAMTS3.	hypericin	0-9	ADAM metallopeptidase with thrombospondin type 1 motif 3	Homo sapiens	97-104
24694757-11	2014	The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area.	hypericin	58-60	vascular endothelial growth factor A	Rattus norvegicus	14-18
24694757-11	2014	The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area.	hypericin	58-60	transforming growth factor, beta 1	Rattus norvegicus	23-28
24694757-11	2014	The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area.	hypericin	58-60	vascular endothelial growth factor A	Rattus norvegicus	124-128
24694757-11	2014	The increased VEGF and TGF-b expression following PHT and HP treatment strongly indicate that PHT and HP treatment promotes VEGF and TGF-b production and action in the burn wound area.	hypericin	58-60	transforming growth factor, beta 1	Rattus norvegicus	133-138
24739262-3	2014	Phosphorylation of the gamma subunit of PKC enzyme was assayed by western blotting in the periaqueductal grey matter (PAG) from rodents co-administered with morphine and hypericin and was prevented in rodent PAG by SJW or hypericin co-administration with morphine, inducing a potentiation of morphine analgesia in thermal pain.	hypericin	170-179	proline rich transmembrane protein 2	Homo sapiens	40-43
24739262-3	2014	Phosphorylation of the gamma subunit of PKC enzyme was assayed by western blotting in the periaqueductal grey matter (PAG) from rodents co-administered with morphine and hypericin and was prevented in rodent PAG by SJW or hypericin co-administration with morphine, inducing a potentiation of morphine analgesia in thermal pain.	hypericin	222-231	proline rich transmembrane protein 2	Homo sapiens	40-43
25237623-6	2013	Under this systemic dual targeting strategy, a vascular disrupting agent first selectively causes massive tumor necrosis that is followed by iodine-131 labeled-hypericin ((123)I-Hyp), a necrosis-avid compound that kills the residual cancer cells by crossfire effect of beta radiation.	hypericin	160-169	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	178-181
24503057-3	2014	OBJECTIVE: Therefore we investigated whether LPS-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) influences hypericin and protoporphyrin IX (PpIX) accumulation, and their photocytotoxicity.	hypericin	133-142	interleukin 6	Homo sapiens	101-114
24503057-3	2014	OBJECTIVE: Therefore we investigated whether LPS-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) influences hypericin and protoporphyrin IX (PpIX) accumulation, and their photocytotoxicity.	hypericin	133-142	interleukin 6	Homo sapiens	116-120
24503057-12	2014	Furthermore, hypericin alone is able to up-regulate the anti-inflammatory cytokines IL-4, -5 and -10, which could be useful to reduce excessive inflammation.	hypericin	13-22	interleukin 4	Homo sapiens	84-100
24508834-2	2014	The imbalance undermines the ability of lewis lung carcinoma (LLC) cells to escape immune attack by increasing the uptake of hypericin-mediated PDT(hyp-PDT) killed lewis lung carcinoma (LLC) cells by homologous dendritic cells (DCs), accompanied by phenotypic maturation (CD80high, CD86high, and CD40high) and functional stimulation (NOhigh, IL-10absent) of dendritic cells as well as subsequent T-cell response.	hypericin	125-134	interleukin 10	Mus musculus	342-347
23816959-3	2013	The objective of this study was to prepare and characterise hypericin-loaded solid lipid nanoparticles (Hy-SLN) for use in photodynamic therapy (PDT).	hypericin	60-69	sarcolipin	Homo sapiens	107-110
23916707-3	2013	In the present study we found that photo-oxidative (phox)-ER stress induced by hypericin-based photodynamic therapy is associated with activation of PERK (an ER sessile, stress sensor), robust induction of CHOP (a pro-apoptotic transcription factor) and induction of Bim and Noxa (accompanied by an eventual drop in Mcl-1 levels).	hypericin	79-88	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	149-153
23916707-3	2013	In the present study we found that photo-oxidative (phox)-ER stress induced by hypericin-based photodynamic therapy is associated with activation of PERK (an ER sessile, stress sensor), robust induction of CHOP (a pro-apoptotic transcription factor) and induction of Bim and Noxa (accompanied by an eventual drop in Mcl-1 levels).	hypericin	79-88	DNA damage inducible transcript 3	Homo sapiens	206-210
23916707-3	2013	In the present study we found that photo-oxidative (phox)-ER stress induced by hypericin-based photodynamic therapy is associated with activation of PERK (an ER sessile, stress sensor), robust induction of CHOP (a pro-apoptotic transcription factor) and induction of Bim and Noxa (accompanied by an eventual drop in Mcl-1 levels).	hypericin	79-88	BCL2 like 11	Homo sapiens	267-270
23916707-3	2013	In the present study we found that photo-oxidative (phox)-ER stress induced by hypericin-based photodynamic therapy is associated with activation of PERK (an ER sessile, stress sensor), robust induction of CHOP (a pro-apoptotic transcription factor) and induction of Bim and Noxa (accompanied by an eventual drop in Mcl-1 levels).	hypericin	79-88	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	275-279
23916707-3	2013	In the present study we found that photo-oxidative (phox)-ER stress induced by hypericin-based photodynamic therapy is associated with activation of PERK (an ER sessile, stress sensor), robust induction of CHOP (a pro-apoptotic transcription factor) and induction of Bim and Noxa (accompanied by an eventual drop in Mcl-1 levels).	hypericin	79-88	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	316-321
23618281-1	2013	A water-soluble inclusion complex of hypericin (HY) with beta-cyclodextrin polymer (CDP) was achieved by supramolecular interactions between HY and CDP.	hypericin	37-46	cut like homeobox 1	Homo sapiens	57-88
23807226-0	2013	Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases.	hypericin	0-9	interleukin 6	Homo sapiens	40-53
23807226-0	2013	Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases.	hypericin	0-9	caspase 6	Homo sapiens	159-167
23807226-5	2013	Here, we investigated the ability of PDT in association with hypericin (HY) to induce tumor cell apoptosis by facilitating the induction of reactive oxygen species (ROS) and secretion of Th1/Th2/Th17 cytokines in human hepatocellular liver carcinoma cell line (HepG2) cells.	hypericin	61-70	negative elongation factor complex member C/D	Homo sapiens	187-190
23690187-0	2013	Effect of hypericin on the ADAMTS-9 and ADAMTS-8 gene expression in MCF7 breast cancer cells.	hypericin	10-19	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	27-35
23479448-0	2013	Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action.	hypericin	82-91	BCL2 apoptosis regulator	Homo sapiens	0-5
23479448-7	2013	We show the localization of Bax and Bak in U-87 MG human glioma cells incubated with photosensitizer hypericin (Hyp) before and after photodynamic action.	hypericin	101-110	BCL2 associated X, apoptosis regulator	Homo sapiens	28-31
23479448-7	2013	We show the localization of Bax and Bak in U-87 MG human glioma cells incubated with photosensitizer hypericin (Hyp) before and after photodynamic action.	hypericin	101-110	BCL2 antagonist/killer 1	Homo sapiens	36-39
23690187-0	2013	Effect of hypericin on the ADAMTS-9 and ADAMTS-8 gene expression in MCF7 breast cancer cells.	hypericin	10-19	ADAM metallopeptidase with thrombospondin type 1 motif 8	Homo sapiens	40-48
23690187-1	2013	AIM: To investigate the effects of hypericin which is obtained from the plant Hypericum perforatum on the expression and the regulation of ADAMTS8 and ADAMTS9 genes in MCF7 breast cancer cells and on the viability of these cells.	hypericin	35-44	ADAM metallopeptidase with thrombospondin type 1 motif 8	Homo sapiens	139-146
23690187-1	2013	AIM: To investigate the effects of hypericin which is obtained from the plant Hypericum perforatum on the expression and the regulation of ADAMTS8 and ADAMTS9 genes in MCF7 breast cancer cells and on the viability of these cells.	hypericin	35-44	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	151-158
23690187-6	2013	RESULTS: ADAMTS9 expression in MCF7 cells were increased 1.8 and 3.6 fold with the use of 2 and 10 microl/mL of hypericin, respectively; and decreased 0.7 fold with the use of 50 microl/mL of hypericin.	hypericin	112-121	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	9-16
23690187-6	2013	RESULTS: ADAMTS9 expression in MCF7 cells were increased 1.8 and 3.6 fold with the use of 2 and 10 microl/mL of hypericin, respectively; and decreased 0.7 fold with the use of 50 microl/mL of hypericin.	hypericin	192-201	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	9-16
23690187-10	2013	Hypericin increases the expression of ADAMTS9, therefore, it may show its antitumoral and antiapoptotic effects by means of ADAMTS9.	hypericin	0-9	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	38-45
23690187-10	2013	Hypericin increases the expression of ADAMTS9, therefore, it may show its antitumoral and antiapoptotic effects by means of ADAMTS9.	hypericin	0-9	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	124-131
22892582-0	2012	Identifying the sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) as a potential target for hypericin--a theoretical study.	hypericin	91-100	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	16-56
23254377-10	2013	Since hypericin showed PKC blocking properties, a role of PKC as an upstream modulator of these transcription factors was hypothesized.	hypericin	6-15	protein kinase C gamma	Homo sapiens	23-26
23254377-10	2013	Since hypericin showed PKC blocking properties, a role of PKC as an upstream modulator of these transcription factors was hypothesized.	hypericin	6-15	protein kinase C gamma	Homo sapiens	58-61
23254377-11	2013	NO donors increased expression and phosphorylation of protein kinase C (PKC) gamma and epsilon isoforms, molecular events prevented by SJW or hypericin.	hypericin	142-151	protein kinase C gamma	Homo sapiens	54-82
23254377-12	2013	CONCLUSIONS: SJW reversed NO-induced nociceptive hypersensitivity through the blockade of a supraspinal signaling pathway involving a PKC-dependent CREB, STAT1 and NF-kappaB activation due to presence of hypericin.	hypericin	204-213	protein kinase C gamma	Homo sapiens	134-137
23160804-6	2013	The maximal relative luciferase activity level of HSPA1A (HSP70-1) induced by hypericin-PDT was nearly nine times that of the control.	hypericin	78-87	heat shock protein family A (Hsp70) member 1A	Homo sapiens	50-56
23160804-6	2013	The maximal relative luciferase activity level of HSPA1A (HSP70-1) induced by hypericin-PDT was nearly nine times that of the control.	hypericin	78-87	heat shock protein family A (Hsp70) member 1A	Homo sapiens	58-65
22581390-11	2013	In contrast, a 20 % increase in cell viability was seen with 1 J/cm(2) and 20 mW and 0.25 muM hypericin.	hypericin	94-103	latexin	Homo sapiens	90-93
22581390-12	2013	Overall, this study highlights an optimised protocol for hypericin-induced photorejuvenative therapy using laser light and proposes that parameters of 0.25 muM hypericin as a photosensitiser activated via a dosage of 1 J/cm(2) yellow laser light produces an effective in vitro outcome to be considered as an important contribution towards optimising PDRT.	hypericin	160-169	latexin	Homo sapiens	156-159
23509735-9	2013	SCC cells of recessive dystrophic EB (RDEB) accumulate less hypericin or PpIX than nonmalignant RDEB cells.	hypericin	60-69	serpin family B member 3	Homo sapiens	0-3
22722579-4	2013	A similar pattern of sensitivity was observed when we exposed the SCC cells to hydrogen peroxide or hypericin photodynamic treatment, which both generate mainly oxidative stress.	hypericin	100-109	serpin family B member 3	Homo sapiens	66-69
22892582-0	2012	Identifying the sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) as a potential target for hypericin--a theoretical study.	hypericin	91-100	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	58-63
22892582-2	2012	In the present study computational docking and molecular dynamics simulations are applied to investigate possible interactions between hypericin and the Ca(2+) pump SERCA as proposed in the literature.	hypericin	135-144	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	165-170
22892582-3	2012	Hypericin was found to bind strongly both in pockets within the transmembrane region and in the cytosolic region of the protein, although the two studied isoforms of SERCA differ slightly in their preferred binding sites.	hypericin	0-9	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	166-171
22892582-4	2012	The calculated binding energies for hypericin in the four investigated sites were of the same magnitude as for thapsigargin (TG), the most potent SERCA inhibitor, or in the range between TG and di-tert-butylhydroquinone (BHQ), which is also known to possess inhibitory activity.	hypericin	36-45	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	146-151
22892582-8	2012	Hypericin most likely binds to both isoforms of SERCA and acts as an inhibitor or, under light irradiation, as a singlet oxygen generator that in turn degrades the protein or induces lipid peroxidation.	hypericin	0-9	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	48-53
27721334-0	2011	Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.	hypericin	26-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	58-63
20933443-2	2012	PATIENTS AND METHODS: Clinical studies were done on a series of 60 bladder cancer biopsies obtained from 28 patients who received intravesical instillations with 8 muM hypericin.	hypericin	168-177	latexin	Homo sapiens	164-167
20933443-12	2012	We have thus identified the effects of alteration of E-cadherin-catenin complex and transformed intercellular junction in the modified paracellular uptake of hypericin that provides the rationale for using this photosensitizer in photodynamic diagnosis of bladder carcinoma.	hypericin	158-167	cadherin 1	Homo sapiens	53-63
22739985-6	2012	Hypericin-mediated photo-oxidative ER damage induced Perk-dependent cell death and led to a significant decrease in the levels of miRNAs belonging to miR-106b-25 cluster in wild-type (WT) but not in Perk-/- MEFs.	hypericin	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	53-57
22193987-0	2012	Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.	hypericin	0-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	107-112
22193987-0	2012	Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.	hypericin	0-9	calreticulin	Homo sapiens	117-129
22193987-5	2012	Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT).	hypericin	54-63	heat shock protein family A (Hsp70) member 4	Homo sapiens	110-115
22193987-5	2012	Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT).	hypericin	54-63	calreticulin	Homo sapiens	120-132
21103512-0	2011	Human serum albumin as key mediator of the differential accumulation of hypericin in normal urothelial cell spheroids versus urothelial cell carcinoma spheroids.	hypericin	72-81	albumin	Homo sapiens	12-19
20883830-6	2011	For the St. John"s Wort extract and its single constituents hypericin, pseudohypericin, and quercetin, inhibition exhibited a remarkable dependency on the CYP1A1 genotype.	hypericin	60-69	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	155-161
21106380-1	2011	Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin.	hypericin	181-190	thioredoxin reductase 1	Homo sapiens	11-16
21106380-1	2011	Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin.	hypericin	181-190	thioredoxin reductase 2	Homo sapiens	37-42
21106380-1	2011	Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin.	hypericin	181-190	thioredoxin	Homo sapiens	44-55
21106380-2	2011	Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40muM) being far more effective than hypericin (IC(50)=157.08muM).	hypericin	6-15	thioredoxin reductase 1	Homo sapiens	61-66
21106380-3	2011	In turn, the IC(50) values measured toward TrxR2 were 7.45muM for pseudohypericin and 43.12muM for hypericin.	hypericin	72-81	thioredoxin reductase 2	Homo sapiens	43-48
21106380-10	2011	As the thioredoxin system is highly overexpressed in cancer cells, its inhibition by hypericin and pseudohypericin, natural compounds showing appreciable anticancer properties, might offer new clues on their mechanism of action and open interesting perspectives for future tumor therapies.	hypericin	85-94	thioredoxin	Homo sapiens	7-18
21114669-1	2011	Steady-state and time-resolved fluorescence spectroscopy have been used for the study of the incorporation kinetics of hypericin (Hyp) into low-density lipoproteins (LDL).	hypericin	119-128	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	130-133
21103512-2	2011	To this end a bladder instillation fluid is prepared in which the water-insoluble hypericin is solubilized by the presence of human serum albumin (HSA) to which the compound binds.	hypericin	82-91	albumin	Homo sapiens	138-145
21103512-2	2011	To this end a bladder instillation fluid is prepared in which the water-insoluble hypericin is solubilized by the presence of human serum albumin (HSA) to which the compound binds.	hypericin	82-91	albumin	Homo sapiens	147-150
21103512-6	2011	Our data show that when hypericin is solubilized by HSA, an excellent differentiation in distribution of hypericin in normal urothelial spheroids and malignant spheroids is observed, clearly suggesting a key role for albumin in the specific localization of hypericin in non-muscle-invasive bladder tumours.	hypericin	24-33	albumin	Homo sapiens	52-55
21103512-6	2011	Our data show that when hypericin is solubilized by HSA, an excellent differentiation in distribution of hypericin in normal urothelial spheroids and malignant spheroids is observed, clearly suggesting a key role for albumin in the specific localization of hypericin in non-muscle-invasive bladder tumours.	hypericin	24-33	albumin	Homo sapiens	217-224
21103512-6	2011	Our data show that when hypericin is solubilized by HSA, an excellent differentiation in distribution of hypericin in normal urothelial spheroids and malignant spheroids is observed, clearly suggesting a key role for albumin in the specific localization of hypericin in non-muscle-invasive bladder tumours.	hypericin	105-114	albumin	Homo sapiens	52-55
21103512-6	2011	Our data show that when hypericin is solubilized by HSA, an excellent differentiation in distribution of hypericin in normal urothelial spheroids and malignant spheroids is observed, clearly suggesting a key role for albumin in the specific localization of hypericin in non-muscle-invasive bladder tumours.	hypericin	105-114	albumin	Homo sapiens	52-55
21103512-7	2011	Furthermore, PDT results show that both the hypericin-PDT effect on tumour spheroids and the selective character of the treatment can significantly be increased by the presence of HSA.	hypericin	44-53	albumin	Homo sapiens	180-183
21175347-0	2011	Photoactivated hypericin induces downregulation of HER2 gene expression.	hypericin	15-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	51-55
21175347-3	2011	The present study shows the effect of photoactivated hypericin on the expression of the human epidermal growth factor receptor 2 (HER2) oncogene at both the mRNA and the protein level in SKBR-3 and MCF-7 breast adenocarcinoma cell lines.	hypericin	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	94-128
21175347-3	2011	The present study shows the effect of photoactivated hypericin on the expression of the human epidermal growth factor receptor 2 (HER2) oncogene at both the mRNA and the protein level in SKBR-3 and MCF-7 breast adenocarcinoma cell lines.	hypericin	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
19932626-3	2010	In line with our expectations, combined treatment led to down-regulation of Bcl-2 and up-regulation of Bax in both cell lines as well as to suppression of Akt and Erk1/2 phosphorylation induced by photoactivated hypericin in MCF-7 cells.	hypericin	212-221	AKT serine/threonine kinase 1	Homo sapiens	155-158
20718930-5	2010	First, we proved that the dark pause of 6 h, but not 1 h, resulted in better cell survival with suppressed phosphatidylserine externalization, decreased reactive oxygen species production and hypericin content as well as altered expression of HSP70, GRP94, clusterin, nuclear factor (NF)-kappaB, IkappaB-alpha or Mcl-1.	hypericin	192-201	CCR4-NOT transcription complex subunit 1	Homo sapiens	49-56
20718930-8	2010	Therefore, we predict involvement of another signaling pathway, located upstream from NF-kappaB, responsible for onset of resistance to photodynamic therapy with hypericin in colon adenocarcinoma cells HT-29.	hypericin	162-171	nuclear factor kappa B subunit 1	Homo sapiens	86-95
20196639-5	2010	Using UGT1A6-infected Sf9 insect cells, calphostin-C and hypericin showed three times more potent inhibition of serotonin glucuronidation in treated whole cells versus cell lysates.	hypericin	57-66	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	6-12
20429274-5	2010	It was concluded that H-bonds of hypericin play a significant role in the interaction with human serum albumin.	hypericin	33-42	albumin	Homo sapiens	97-110
21949677-0	2011	Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.	hypericin	111-120	heat shock protein 90 alpha family class A member 1	Homo sapiens	67-72
21949677-2	2011	Hypericin is the only known exogenous reagent that can induce forced poly-ubiquitination and accelerated degradation of heat shock protein 90 (Hsp90) in cancer cells.	hypericin	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	120-141
21949677-2	2011	Hypericin is the only known exogenous reagent that can induce forced poly-ubiquitination and accelerated degradation of heat shock protein 90 (Hsp90) in cancer cells.	hypericin	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	143-148
21949677-5	2011	We show here that hypericin also induces enhanced degradation of hypoxia-inducible factor 1alpha (HIF-1alpha) in two human tumor cell lines, U87-MG glioblastoma and RCC-C2VHL-/- renal cell carcinoma and in the non-malignant ARPE19 retinal pigment epithelial cell line.	hypericin	18-27	hypoxia inducible factor 1 subunit alpha	Homo sapiens	65-96
21949677-5	2011	We show here that hypericin also induces enhanced degradation of hypoxia-inducible factor 1alpha (HIF-1alpha) in two human tumor cell lines, U87-MG glioblastoma and RCC-C2VHL-/- renal cell carcinoma and in the non-malignant ARPE19 retinal pigment epithelial cell line.	hypericin	18-27	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-108
21949677-6	2011	The hypericin-accelerated turnover of HIF-1alpha, the regulatory precursor of the HIF-1 transcription factor which promotes hypoxic stress and angiogenic responses, overcomes the physiologic HIF-1alpha protein stabilization which occurs in hypoxic cells.	hypericin	4-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	38-48
21949677-6	2011	The hypericin-accelerated turnover of HIF-1alpha, the regulatory precursor of the HIF-1 transcription factor which promotes hypoxic stress and angiogenic responses, overcomes the physiologic HIF-1alpha protein stabilization which occurs in hypoxic cells.	hypericin	4-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	191-201
21949677-7	2011	The hypericin effect also eliminates the high HIF-1alpha levels expressed constitutively in the von-Hippel Lindau protein (pVHL)-deficient RCC-C2VHL-/- renal cell carcinoma cell line.	hypericin	4-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	46-56
21949677-8	2011	Unlike the normal ubiquitin-proteasome pathway-dependent turnover of HIF-alpha proteins which occurs in normoxia, the hypericin-induced HIF-1alpha catabolism can occur independently of cellular oxygen levels or pVHL-promoted ubiquitin ligation of HIF-1alpha.	hypericin	118-127	von Hippel-Lindau tumor suppressor	Homo sapiens	211-215
21949677-8	2011	Unlike the normal ubiquitin-proteasome pathway-dependent turnover of HIF-alpha proteins which occurs in normoxia, the hypericin-induced HIF-1alpha catabolism can occur independently of cellular oxygen levels or pVHL-promoted ubiquitin ligation of HIF-1alpha.	hypericin	118-127	hypoxia inducible factor 1 subunit alpha	Homo sapiens	136-146
21949677-9	2011	It is mediated by lysosomal cathepsin-B enzymes with cathepsin-B activity being optimized in the cells through hypericin-mediated reduction in intracellular pH.	hypericin	111-120	cathepsin B	Homo sapiens	28-39
21949677-9	2011	It is mediated by lysosomal cathepsin-B enzymes with cathepsin-B activity being optimized in the cells through hypericin-mediated reduction in intracellular pH.	hypericin	111-120	cathepsin B	Homo sapiens	53-64
21949677-10	2011	Our findings suggest that hypericin may potentially be useful in preventing growth of tumors in which HIF-1alpha plays pivotal roles, and in pVHL ablated tumor cells such as renal cell carcinoma through elimination of elevated HIF-1alpha contents in these cells, scaling down the excessive angiogenesis which characterizes these tumors.	hypericin	26-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	102-112
21949677-10	2011	Our findings suggest that hypericin may potentially be useful in preventing growth of tumors in which HIF-1alpha plays pivotal roles, and in pVHL ablated tumor cells such as renal cell carcinoma through elimination of elevated HIF-1alpha contents in these cells, scaling down the excessive angiogenesis which characterizes these tumors.	hypericin	26-35	hypoxia inducible factor 1 subunit alpha	Homo sapiens	227-237
19932626-0	2010	Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells.	hypericin	74-83	BCL2 apoptosis regulator	Homo sapiens	19-24
19932626-0	2010	Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells.	hypericin	74-83	AKT serine/threonine kinase 1	Homo sapiens	29-32
19932626-2	2010	Since genistein is known to suppress Bcl-2 expression, we predicted that photodynamic therapy with hypericin might benefit from mutual therapeutic combination.	hypericin	99-108	BCL2 apoptosis regulator	Homo sapiens	37-42
19932626-3	2010	In line with our expectations, combined treatment led to down-regulation of Bcl-2 and up-regulation of Bax in both cell lines as well as to suppression of Akt and Erk1/2 phosphorylation induced by photoactivated hypericin in MCF-7 cells.	hypericin	212-221	mitogen-activated protein kinase 3	Homo sapiens	163-169
19862414-0	2009	The role of p53 in the efficiency of photodynamic therapy with hypericin and subsequent long-term survival of colon cancer cells.	hypericin	63-72	tumor protein p53	Homo sapiens	12-15
19912559-0	2010	Degradation of HER2 receptor through hypericin-mediated photodynamic therapy.	hypericin	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-19
19912559-2	2010	Here, we report for the first time the use of hypericin-mediated photodynamic therapy (HY-PDT) in combination with a selective HER2 inhibitor (AG 825) on SKBR-3, a HER2 overexpressing human breast adenocarcinoma cell line.	hypericin	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	164-168
20024169-0	2009	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.	hypericin	63-72	ATP binding cassette subfamily C member 1	Homo sapiens	26-30
20024169-0	2009	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.	hypericin	63-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	35-39
20024169-5	2009	We report here for the first time increased activity of MRP1 and BCRP in HT-29 colon cancer cells treated with hypericin per se.	hypericin	111-120	ATP binding cassette subfamily C member 1	Homo sapiens	56-60
20024169-5	2009	We report here for the first time increased activity of MRP1 and BCRP in HT-29 colon cancer cells treated with hypericin per se.	hypericin	111-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	65-69
20024169-6	2009	On the contrary, pre-treatment with proadifen (SKF525A) affected the function of MRP1 and BCRP leading to increased hypericin content, which might indicate a possible link between proadifen and these ABC transporter proteins.	hypericin	116-125	ATP binding cassette subfamily C member 1	Homo sapiens	81-85
20024169-6	2009	On the contrary, pre-treatment with proadifen (SKF525A) affected the function of MRP1 and BCRP leading to increased hypericin content, which might indicate a possible link between proadifen and these ABC transporter proteins.	hypericin	116-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	90-94
20024169-8	2009	In conclusion, our study suggests that drug efflux transporters MRP1 and BCRP affect the pharmacokinetics of hypericin in HT-29 colon adenocarcinoma cells, and the action of hypericin-mediated PDT (HY-PDT) should be modulated by pre-treatment with their specific inhibitors.	hypericin	109-118	ATP binding cassette subfamily C member 1	Homo sapiens	64-68
20024169-8	2009	In conclusion, our study suggests that drug efflux transporters MRP1 and BCRP affect the pharmacokinetics of hypericin in HT-29 colon adenocarcinoma cells, and the action of hypericin-mediated PDT (HY-PDT) should be modulated by pre-treatment with their specific inhibitors.	hypericin	109-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-77
20024169-8	2009	In conclusion, our study suggests that drug efflux transporters MRP1 and BCRP affect the pharmacokinetics of hypericin in HT-29 colon adenocarcinoma cells, and the action of hypericin-mediated PDT (HY-PDT) should be modulated by pre-treatment with their specific inhibitors.	hypericin	174-183	ATP binding cassette subfamily C member 1	Homo sapiens	64-68
20024169-8	2009	In conclusion, our study suggests that drug efflux transporters MRP1 and BCRP affect the pharmacokinetics of hypericin in HT-29 colon adenocarcinoma cells, and the action of hypericin-mediated PDT (HY-PDT) should be modulated by pre-treatment with their specific inhibitors.	hypericin	174-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-77
18771933-1	2008	In our previous study we have proved that colon cancer cells HT-29 pre-treated with specific 5-lipoxygenase inhibitor MK-886 became more susceptible to photodynamic therapy (PDT) with hypericin and we also found that this mutual combination induced cell cycle arrest and stimulated onset of apoptosis (Kleban et al., 2007.	hypericin	184-193	arachidonate 5-lipoxygenase	Homo sapiens	93-107
19496992-0	2009	Role of p38 MAPKs in hypericin photodynamic therapy-induced apoptosis of nasopharyngeal carcinoma cells.	hypericin	21-30	mitogen-activated protein kinase 14	Homo sapiens	8-11
18814910-5	2009	In the presence of the photosensitising agents acridine orange (100 nM) or hypericin (10 nM), the sensitivity of light-induced TRPA1 activation was increased and extended towards the visible spectrum.	hypericin	75-84	transient receptor potential cation channel subfamily A member 1	Homo sapiens	127-132
19186045-4	2009	The down-regulation of K(V) 1.5, K(V) 2.1 and K(V) 3.4 channel expression and inhibition of whole-cell K currents (I(K)(V)) induced by 15-HETE were rescued and restored, respectively, by hypericin.	hypericin	187-196	potassium voltage-gated channel subfamily A member 5	Rattus norvegicus	23-50
18949433-13	2008	Enhancement of the hypericin concentration (up to 12.5 microM) and illumination time of up to 40 min resulted in a decrease of tumor cell viability (HUH6 99.8+/-2.4%, HepT1 99+/-2%, HepG2 98.4+/-1.6%, p<0.05), proliferative activity and complete apoptosis of all cells in all investigated cell lines.	hypericin	19-28	selenoprotein I	Homo sapiens	167-172
18687658-4	2008	We now show the effect of erythropoietin treatment on the response of A2780 and SKOV3 ovarian carcinoma cell lines to photodynamic therapy (PDT) using hypericin.	hypericin	151-160	erythropoietin	Homo sapiens	26-40
18687658-5	2008	SKOV3 exhibited an increased resistance to hypericin when cells were treated with erythropoietin.	hypericin	43-52	erythropoietin	Homo sapiens	82-96
18687658-9	2008	Erythropoietin-treated SKOV3 cells exhibited decreased apoptosis induced by hypericin, an effect that was blocked by the phosphoinositide 3-kinase/Akt inhibitor wortmannin.	hypericin	76-85	erythropoietin	Homo sapiens	0-14
18687658-9	2008	Erythropoietin-treated SKOV3 cells exhibited decreased apoptosis induced by hypericin, an effect that was blocked by the phosphoinositide 3-kinase/Akt inhibitor wortmannin.	hypericin	76-85	AKT serine/threonine kinase 1	Homo sapiens	147-150
18355860-0	2008	Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin.	hypericin	29-38	cadherin 1	Homo sapiens	134-144
18355860-6	2008	RESULTS: Data showed that in the presence of serum the accumulation of hypericin in spheroids was inversely associated with the level of E-cadherin expressed by the T-24 transfectants used, whereas in the absence of serum differential accumulation of the compound was completely abolished.	hypericin	71-80	cadherin 1	Homo sapiens	137-147
18355860-8	2008	The outcome of this study strongly suggests that E-cadherin is the key mediator in the selective accumulation of hypericin in superficial bladder cancer after intravesical instillation in humans.	hypericin	113-122	cadherin 1	Homo sapiens	49-59
18435618-4	2008	There is also evidence of energy transfer from tryptophans of the constituent protein, apoB-100, to hypericin in LDL.	hypericin	100-109	apolipoprotein B	Homo sapiens	87-95
18046482-6	2007	In this study we evaluated the combination of hypericin-mediated PDT and Avastin on VEGF levels as well as its effect on overall tumor response.	hypericin	46-55	vascular endothelial growth factor A	Homo sapiens	84-88
18334941-11	2008	Treatment with SJW or hypericin reduced phosphorylation of ERK in the retina.	hypericin	22-31	mitogen-activated protein kinase 1	Mus musculus	59-62
18551893-1	2008	Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway.	hypericin	0-9	tumor protein p53	Homo sapiens	111-114
17786271-0	2007	Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.	hypericin	10-19	vascular endothelial growth factor A	Homo sapiens	71-105
17786271-4	2007	However, as hypericin-mediated PDT primarily targets tumor vasculature, it induces certain pro-angiogenic factors such as vascular endothelial growth factor (VEGF) in the tumor tissue as a result of hypoxia.	hypericin	12-21	vascular endothelial growth factor A	Homo sapiens	122-156
17786271-4	2007	However, as hypericin-mediated PDT primarily targets tumor vasculature, it induces certain pro-angiogenic factors such as vascular endothelial growth factor (VEGF) in the tumor tissue as a result of hypoxia.	hypericin	12-21	vascular endothelial growth factor A	Homo sapiens	158-162
17786271-5	2007	This study examines the role of hypericin-mediated photodynamic therapy in stimulating the expression of key angiogenesis growth factor VEGF in order to elucidate the process of tumor angiogenesis in nasopharyngeal carcinoma xenografts.	hypericin	32-41	vascular endothelial growth factor A	Homo sapiens	136-140
17786271-8	2007	VEGF was measured in the control and hypericin-PDT treated tumors.	hypericin	37-46	vascular endothelial growth factor A	Homo sapiens	0-4
17786271-10	2007	At 72 h post hypericin-PDT, VEGF levels were upregulated indicating the initiation of regrowth in tumors.	hypericin	13-22	vascular endothelial growth factor A	Homo sapiens	28-32
17786271-11	2007	The use of angiogenesis inhibitor, celebrex, along with hypericin-PDT downregulated the human VEGF levels suggesting that angiogenesis inhibitors can be used to improve the outcome of hypericin-PDT in nasopharyngeal carcinomas.	hypericin	56-65	vascular endothelial growth factor A	Homo sapiens	94-98
17786271-11	2007	The use of angiogenesis inhibitor, celebrex, along with hypericin-PDT downregulated the human VEGF levels suggesting that angiogenesis inhibitors can be used to improve the outcome of hypericin-PDT in nasopharyngeal carcinomas.	hypericin	184-193	vascular endothelial growth factor A	Homo sapiens	94-98
27263770-0	2007	Hypericium perforatum extract (St. John"s Wort) and hypericin induce apoptosis in leukemic HL-60 cells by effecting h-TERT activity.	hypericin	52-61	telomerase reverse transcriptase	Homo sapiens	118-122
27263770-9	2007	Total RNA was isolated concomittantly and h-TERT mRNA expression was analyzed at Light Cycler Real-time online polymerase chain reaction and it was found that the mRNA expression was meaningfully decreased at 48th hour of incubation of cells with hypericin.	hypericin	247-256	telomerase reverse transcriptase	Homo sapiens	44-48
27263770-10	2007	According to results of this study, we have shown that hypericin, as main cytotoxic compound of Hypericium perforatum L, induces apoptosis in HL-60 cells via effecting h-TERT mRNA expression.	hypericin	55-64	telomerase reverse transcriptase	Homo sapiens	170-174
17219054-0	2007	Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy.	hypericin	115-124	heme oxygenase 1	Homo sapiens	13-29
17576381-7	2007	The presence of hypericin in irradiated hRPE cells significantly changed the redox equilibrium of glutathione and a decrease in the activity of glutathione reductase.	hypericin	16-25	glutathione-disulfide reductase	Homo sapiens	144-165
17880503-6	2007	Hypericin-like pigments are involved in some well-known photophobic reactions but other pigments (rhodopsin and flavins) are also involved in photoresponses in heterotrichs and other protists.	hypericin	0-9	rhodopsin	Homo sapiens	98-107
17219054-8	2007	Altogether these results indicate that stimulation of HO-1 expression by hypericin-PDT is a cytoprotective mechanism governed by the p38(MAPK) and PI3K pathways, likely through the control of the nuclear availability of the Nrf2 pool.	hypericin	73-82	heme oxygenase 1	Homo sapiens	54-58
17219054-8	2007	Altogether these results indicate that stimulation of HO-1 expression by hypericin-PDT is a cytoprotective mechanism governed by the p38(MAPK) and PI3K pathways, likely through the control of the nuclear availability of the Nrf2 pool.	hypericin	73-82	mitogen-activated protein kinase 14	Homo sapiens	133-136
17219054-8	2007	Altogether these results indicate that stimulation of HO-1 expression by hypericin-PDT is a cytoprotective mechanism governed by the p38(MAPK) and PI3K pathways, likely through the control of the nuclear availability of the Nrf2 pool.	hypericin	73-82	NFE2 like bZIP transcription factor 2	Homo sapiens	224-228
16545574-0	2006	Pre-treatment of HT-29 cells with 5-LOX inhibitor (MK-886) induces changes in cell cycle and increases apoptosis after photodynamic therapy with hypericin.	hypericin	145-154	arachidonate 5-lipoxygenase	Homo sapiens	34-39
17385073-0	2007	Hypericin photoactivation triggers down-regulation of matrix metalloproteinase-9 expression in well-differentiated human nasopharyngeal cancer cells.	hypericin	0-9	matrix metallopeptidase 9	Homo sapiens	54-80
17385073-2	2007	The present study evaluated the expression of matrix metalloproteinase-9 (MMP-9) following hypericin-PDT in well-differentiated HK1 NPC cells.	hypericin	91-100	matrix metallopeptidase 9	Homo sapiens	46-72
17385073-2	2007	The present study evaluated the expression of matrix metalloproteinase-9 (MMP-9) following hypericin-PDT in well-differentiated HK1 NPC cells.	hypericin	91-100	matrix metallopeptidase 9	Homo sapiens	74-79
17385073-3	2007	Down-regulation of MMP-9 by hypericin-PDT was observed at the mRNA level in HK1 cells in vitro and in vivo and at the protein level in vitro.	hypericin	28-37	matrix metallopeptidase 9	Homo sapiens	19-24
17385073-6	2007	However, incubation of untreated HK1 cells with exogenous GM-CSF abrogated the reduction of MMP-9 production in hypericin-PDT-treated cells.	hypericin	112-121	colony stimulating factor 2	Homo sapiens	58-64
17385073-6	2007	However, incubation of untreated HK1 cells with exogenous GM-CSF abrogated the reduction of MMP-9 production in hypericin-PDT-treated cells.	hypericin	112-121	matrix metallopeptidase 9	Homo sapiens	92-97
17385073-8	2007	Suppression of MMP-9 by hypericin-PDT may have therapeutic implications.	hypericin	24-33	matrix metallopeptidase 9	Homo sapiens	15-20
17147827-4	2006	The current study defined hypericin PDT in vitro with human SCC cells before the cells were grown as tumor transplants in nude mice and tested as a model for hypericin induced tumor fluorescence and PDT via laser fiberoptics.	hypericin	26-35	serpin family B member 3	Homo sapiens	60-63
17147827-7	2006	RESULTS: In vitro testing revealed a hypericin dose of 0.2-0.5 microg/ml was needed for PDT of the SCC cells with an optimal tumoricidal response seen at the 593 nm light absorption maximum.	hypericin	37-46	serpin family B member 3	Homo sapiens	99-102
17147827-9	2006	CONCLUSION: In this preclinical study, hypericin was tested for 514-593 nm dye laser PDT of human SCC cells in vitro and for KTP532 surgical laser targeting of SCC tumors in mice.	hypericin	39-48	serpin family B member 3	Homo sapiens	98-101
17089067-7	2006	The results showed that hypericin PDT induced necrotic cell death as evidenced by the absence of a subdiploid peak and decreased Annexin-V fluorescence.	hypericin	24-33	annexin A5	Homo sapiens	129-138
16396605-1	2006	A fluorescence imaging technique was used to monitor intracellular localization of protein kinase C (PKC) in U-87 MG human glioma cells in the presence of hypericin (Hyp) and phorbol 12-myristate-13-acetate (PMA).	hypericin	155-164	protein kinase C gamma	Homo sapiens	101-104
16874066-3	2006	In this study we have identified the photodamage to the sarco(endo)plasmic-reticulum Ca(2+)-ATPase (SERCA) pump and consequent loss in the ER-Ca(2+) homeostasis as the most apical molecular events leading to cell death in hypericin-photosensitized cells.	hypericin	222-231	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	56-98
16874066-3	2006	In this study we have identified the photodamage to the sarco(endo)plasmic-reticulum Ca(2+)-ATPase (SERCA) pump and consequent loss in the ER-Ca(2+) homeostasis as the most apical molecular events leading to cell death in hypericin-photosensitized cells.	hypericin	222-231	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	100-105
16874066-7	2006	These results argue that the decision to die in this paradigm of oxidative stress is taken upstream of Bax-dependent MOMP and that the irreversible photodamage to the ER induced by hypericin-PDT acts as a trigger for an autophagic cell death pathway in apoptosis-deficient cells.	hypericin	181-190	BCL2 associated X, apoptosis regulator	Homo sapiens	103-106
16755466-10	2006	MDR1 and CYP3A4 mRNA expression were both induced by single constituents of SJW such as hypericin and hyperforin in a concentration of 10 microM.	hypericin	88-97	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
16755466-10	2006	MDR1 and CYP3A4 mRNA expression were both induced by single constituents of SJW such as hypericin and hyperforin in a concentration of 10 microM.	hypericin	88-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-15
16442130-12	2006	In another study, we observed that long-term exposure of hypericin, kaempferol, quercetin and silibinin resulted in higher MDR-1 mRNA expression in Caco-2 cells.	hypericin	57-66	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
16455754-0	2006	Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy.	hypericin	118-127	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
16455754-0	2006	Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy.	hypericin	118-127	BCL2 antagonist/killer 1	Homo sapiens	77-80
16455754-2	2006	We report that PDT with endoplasmic reticulum (ER)-associating hypericin leads to an immediate loss of SERCA2 protein levels, causing disruption of Ca2+ homeostasis and cell death.	hypericin	63-72	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2	Homo sapiens	103-109
15935550-0	2006	Hypericin-mediated photodynamic therapy elicits differential interleukin-6 response in nasopharyngeal cancer.	hypericin	0-9	interleukin 6	Homo sapiens	61-74
16203156-13	2006	Overall tumour response to hypericin-PDT under low fluence and fluence rate and using a 6h DLI showed increased apoptosis and lower serum VEGF levels.	hypericin	27-36	vascular endothelial growth factor A	Homo sapiens	138-142
16814590-7	2006	The activity of cytosolic and mitochondrial aconitase, an enzyme exquisitely sensitive to oxidation, revealed a dose correlated loss of activity in the mitochondria immediately following hypericin photoactivation.	hypericin	187-196	aconitase 2	Homo sapiens	16-53
15672261-11	2005	Hypericin treatment (6.25-50 microM) inhibited NF-kappaB, caused accumulation of phosphorylated IkappaBalpha, decreased p50 protein levels and induced cleavage of p65 protein in U373 cells.	hypericin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	47-56
16214108-0	2005	Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy.	hypericin	107-116	mitogen-activated protein kinase 14	Homo sapiens	23-31
16214108-2	2005	We show that exposure of bladder cancer cells to hypericin PDT leads to a rapid rise in the cytosolic calcium concentration which is followed by the generation of arachidonic acid by phospholipase A2 (PLA2).	hypericin	49-58	phospholipase A2 group IB	Homo sapiens	183-199
16214108-2	2005	We show that exposure of bladder cancer cells to hypericin PDT leads to a rapid rise in the cytosolic calcium concentration which is followed by the generation of arachidonic acid by phospholipase A2 (PLA2).	hypericin	49-58	phospholipase A2 group IB	Homo sapiens	201-205
16853517-0	2005	Interaction of glutathione S-transferase with hypericin: A photophysical study.	hypericin	46-55	glutathione S-transferase kappa 1	Homo sapiens	15-40
16853517-1	2005	The photophysics of hypericin have been studied in its complex with two different isoforms, A1-1 and P1-1, of the protein glutathione S-transferase (GST).	hypericin	20-29	DXS435E	Homo sapiens	92-105
16853517-1	2005	The photophysics of hypericin have been studied in its complex with two different isoforms, A1-1 and P1-1, of the protein glutathione S-transferase (GST).	hypericin	20-29	glutathione S-transferase kappa 1	Homo sapiens	122-147
16853517-1	2005	The photophysics of hypericin have been studied in its complex with two different isoforms, A1-1 and P1-1, of the protein glutathione S-transferase (GST).	hypericin	20-29	glutathione S-transferase kappa 1	Homo sapiens	149-152
15947580-1	2005	PURPOSE: We investigated the importance of E-cadherin expression on the selective accumulation of hypericin in superficial bladder cancer after intravesical instillation.	hypericin	98-107	cadherin 1	Homo sapiens	43-53
15947580-7	2005	Taken together the data point to an inverse relationship between E-cadherin expression and the permeation of hypericin throughout a 3-dimensional cellular matrix.	hypericin	109-118	cadherin 1	Homo sapiens	65-75
15947580-9	2005	The data show that E-cadherin hampers the permeation of hypericin in spheroids and the loss of intercellular adhesion, present in superficial bladder cancer lesions, can be associated with enhanced hypericin permeation.	hypericin	56-65	cadherin 1	Homo sapiens	19-29
15947580-10	2005	Therefore, E-cadherin expression seems to have a pivotal role in the selective uptake of hypericin after intravesical instillation in human bladders.	hypericin	89-98	cadherin 1	Homo sapiens	11-21
16211256-0	2005	Expression of Y-Box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo.	hypericin	48-57	Y box protein 1	Mus musculus	14-37
16211256-7	2005	Expression of the YB-1 protein may possibly influence the cellular stress response to hypericin-PDT and protect the cells from phototoxicity.	hypericin	86-95	Y box protein 1	Mus musculus	18-22
16853517-2	2005	One molecule of hypericin binds to each of the two GST subunits.	hypericin	16-25	glutathione S-transferase kappa 1	Homo sapiens	51-54
16853517-6	2005	Hypericin binds with high affinity to the GSTs: 0.65 microM for the A1-1 isoform and 0.51 microM for the P1-1 isoform (Biochemistry 2004, 43, 12761-12769).	hypericin	0-9	glutathione S-transferase alpha 1	Homo sapiens	42-46
16853517-6	2005	Hypericin binds with high affinity to the GSTs: 0.65 microM for the A1-1 isoform and 0.51 microM for the P1-1 isoform (Biochemistry 2004, 43, 12761-12769).	hypericin	0-9	S100 calcium binding protein A10	Homo sapiens	105-109
16853517-9	2005	Most importantly, while there is significant singlet oxygen generation from hypericin bound to GST A1-1, binding to GST P1-1 suppresses singlet oxygen generation to almost negligible levels.	hypericin	76-85	glutathione S-transferase alpha 1	Homo sapiens	95-103
16853517-10	2005	The data are rationalized in terms of a simple model in which the hypericin photophysics depends entirely upon the decay of the triplet state by two competing processes, quenching by oxygen to yield singlet oxygen and ionization, the latter of these two are proposed to be modulated by A1-1 and P1-1.	hypericin	66-75	S100 calcium binding protein A10	Homo sapiens	295-299
15672261-11	2005	Hypericin treatment (6.25-50 microM) inhibited NF-kappaB, caused accumulation of phosphorylated IkappaBalpha, decreased p50 protein levels and induced cleavage of p65 protein in U373 cells.	hypericin	0-9	NFKB inhibitor alpha	Homo sapiens	96-108
15672261-11	2005	Hypericin treatment (6.25-50 microM) inhibited NF-kappaB, caused accumulation of phosphorylated IkappaBalpha, decreased p50 protein levels and induced cleavage of p65 protein in U373 cells.	hypericin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	120-123
15672261-11	2005	Hypericin treatment (6.25-50 microM) inhibited NF-kappaB, caused accumulation of phosphorylated IkappaBalpha, decreased p50 protein levels and induced cleavage of p65 protein in U373 cells.	hypericin	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	163-166
15672261-13	2005	Additionally, inhibition of NF-kappaB activity in U373 cells by hypericin was prevented by caspase inhibition.	hypericin	64-73	nuclear factor kappa B subunit 1	Homo sapiens	28-37
15672261-14	2005	Although hypericin clearly inhibits proteasome function, its effect NF-kappaB DNA-binding activity was not exclusively proteasome-dependent.	hypericin	9-18	nuclear factor kappa B subunit 1	Homo sapiens	68-77
15821349-2	2005	In the present studies, we analyzed the dynamic changes in Ca2+ influx and free intracellular Ca2+ concentration ([Ca2+]i) of cultured human retinal pigment epithelial (RPE) cells after stimulation with hypericin in an attempt to elucidate its mechanism as a therapeutic drug for PVR.	hypericin	203-212	carbonic anhydrase 2	Homo sapiens	59-62
15821349-2	2005	In the present studies, we analyzed the dynamic changes in Ca2+ influx and free intracellular Ca2+ concentration ([Ca2+]i) of cultured human retinal pigment epithelial (RPE) cells after stimulation with hypericin in an attempt to elucidate its mechanism as a therapeutic drug for PVR.	hypericin	203-212	carbonic anhydrase 2	Homo sapiens	94-97
15821349-0	2005	The inhibition of CA2+ influx induced by hypericin in cultured human retinal pigment epithelial cells analyzed by confocal imaging.	hypericin	41-50	carbonic anhydrase 2	Homo sapiens	18-21
15821349-2	2005	In the present studies, we analyzed the dynamic changes in Ca2+ influx and free intracellular Ca2+ concentration ([Ca2+]i) of cultured human retinal pigment epithelial (RPE) cells after stimulation with hypericin in an attempt to elucidate its mechanism as a therapeutic drug for PVR.	hypericin	203-212	carbonic anhydrase 2	Homo sapiens	94-97
15821349-7	2005	In contrast, stimulation with higher concentrations of hypericin (1-5 microM) led to a rapid decrease in Ca2+ influx and [Ca2+]i, which was significantly different from those detected without hypericin (control experiments).	hypericin	55-64	carbonic anhydrase 2	Homo sapiens	105-108
15821349-7	2005	In contrast, stimulation with higher concentrations of hypericin (1-5 microM) led to a rapid decrease in Ca2+ influx and [Ca2+]i, which was significantly different from those detected without hypericin (control experiments).	hypericin	55-64	carbonic anhydrase 2	Homo sapiens	122-125
15821349-10	2005	CONCLUSION: In RPE cells, high concentrations of hypericin (1-5 microM) significantly inhibit Ca2+ influx and induce a decrease in [Ca2+]i.	hypericin	49-58	carbonic anhydrase 2	Homo sapiens	94-97
15821349-10	2005	CONCLUSION: In RPE cells, high concentrations of hypericin (1-5 microM) significantly inhibit Ca2+ influx and induce a decrease in [Ca2+]i.	hypericin	49-58	carbonic anhydrase 2	Homo sapiens	132-135
15821349-11	2005	Therefore, hypericin has potential as a therapeutic drug for PVR maybe through its inhibition of the Ca2+ influx pathway.	hypericin	11-20	carbonic anhydrase 2	Homo sapiens	101-104
16132616-2	2005	Extensive angiogenesis induced in the cornea and iris by intra-ocular administration of FGF-2 was effectively inhibited by a minimum of four dose regimens of hypericin (2 mg/kg) administered via the intraperitoneal route at 48 h intervals.	hypericin	158-167	fibroblast growth factor 2	Homo sapiens	88-93
15640377-3	2005	In this study, we aimed to examine the chronic effects of St. John"s wort and its constituents, hyperforin and hypericin, on the expression and function of P-glycoprotein in an intestinal cell line, LS 180.	hypericin	111-120	ATP binding cassette subfamily B member 1	Homo sapiens	156-170
16132616-3	2005	Maximal inhibition was achieved when animal treatment with hypericin was initiated 48 h prior to inoculation of FGF-2.	hypericin	59-68	fibroblast growth factor 2	Homo sapiens	112-117
16132616-5	2005	We show that the activating phosphorylation of extracellular signal-regulated MAP kinases (ERK1/2) is inhibited by hypericin in human retinal pigment epithelial cells and in EA.hy926 cells, an endothelial hybridoma expressing endothelial cell properties.	hypericin	115-124	mitogen-activated protein kinase 3	Homo sapiens	91-97
16059654-3	2005	Here, we attempted to enhance hypericin-induced photocytotoxicity and apoptosis by diazepam, a non-selective ligand of peripheral benzodiazepine receptors (PBR) which seem to play an important role in apoptosis regulation.	hypericin	30-39	translocator protein	Homo sapiens	119-154
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	proline rich transmembrane protein 2	Homo sapiens	151-154
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	proline rich transmembrane protein 2	Homo sapiens	156-172
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	dopamine beta-hydroxylase	Homo sapiens	175-200
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	240-243
15638760-5	2005	In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential.	hypericin	41-50	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	245-260
16059654-3	2005	Here, we attempted to enhance hypericin-induced photocytotoxicity and apoptosis by diazepam, a non-selective ligand of peripheral benzodiazepine receptors (PBR) which seem to play an important role in apoptosis regulation.	hypericin	30-39	translocator protein	Homo sapiens	156-159
15266218-6	2004	Quercetin, hypericin, and kaempferol exhibited a remarkable inhibition of P-gp-mediated efflux of ritonavir by increasing its cellular uptake in these models.	hypericin	11-20	phosphoglycolate phosphatase	Homo sapiens	74-78
15372129-0	2004	Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers.	hypericin	102-111	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	10-26
15072826-0	2004	Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells.	hypericin	19-28	glutathione S-transferase kappa 1	Homo sapiens	44-69
15266218-15	2004	Hypericin, kaempferol, quercetin, and allicin inhibit the efflux and CYP3A4-mediated metabolism of xenobiotics in vitro.	hypericin	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
15072826-4	2004	There was also significant reduction of Glutathione S-transferase (GST) activity in HK1 and CNE-2 NPC cells and in tumor tissues from the NPC/HK1 murine tumor model by hypericin-mediated PDT.	hypericin	168-177	glutathione S-transferase kappa 1	Homo sapiens	40-65
15072826-4	2004	There was also significant reduction of Glutathione S-transferase (GST) activity in HK1 and CNE-2 NPC cells and in tumor tissues from the NPC/HK1 murine tumor model by hypericin-mediated PDT.	hypericin	168-177	glutathione S-transferase kappa 1	Homo sapiens	67-70
15072826-4	2004	There was also significant reduction of Glutathione S-transferase (GST) activity in HK1 and CNE-2 NPC cells and in tumor tissues from the NPC/HK1 murine tumor model by hypericin-mediated PDT.	hypericin	168-177	hexokinase 1	Homo sapiens	84-87
15072826-4	2004	There was also significant reduction of Glutathione S-transferase (GST) activity in HK1 and CNE-2 NPC cells and in tumor tissues from the NPC/HK1 murine tumor model by hypericin-mediated PDT.	hypericin	168-177	hexokinase 1	Homo sapiens	142-145
15072826-5	2004	As antioxidants protect cells against phototoxicity, down-regulation of GST activity would potentiate the efficacy of hypericin-PDT treatment.	hypericin	118-127	glutathione S-transferase kappa 1	Homo sapiens	72-75
14980009-0	2004	Quantitative characterization of direct P-glycoprotein inhibition by St John"s wort constituents hypericin and hyperforin.	hypericin	97-106	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
14767550-0	2004	Modulation of Matrix metalloproteinase-1 in nasopharyngeal cancer cells by photoactivation of hypericin.	hypericin	94-103	matrix metallopeptidase 1	Homo sapiens	14-40
14767550-2	2004	In the present study, we analyzed the effect of hypericin-based photodynamic therapy (PDT) on MMP-1 expression in two nasopharyngeal cancer (NPC) cell lines and an animal tumor model.	hypericin	48-57	matrix metallopeptidase 1	Homo sapiens	94-99
14767550-4	2004	Photoactivation of hypericin, a polycyclic phenanthroperylenedione, elicited an increase in MMP-1 protein and mRNA expression in well differentiated HK1 and poorly differentiated CNE-2 NPC cells in vitro.	hypericin	19-28	matrix metallopeptidase 1	Homo sapiens	92-97
14767550-4	2004	Photoactivation of hypericin, a polycyclic phenanthroperylenedione, elicited an increase in MMP-1 protein and mRNA expression in well differentiated HK1 and poorly differentiated CNE-2 NPC cells in vitro.	hypericin	19-28	hexokinase 1	Homo sapiens	149-152
14767550-5	2004	Similarly, there was up-regulation of MMP1 mRNA expression in hypericin-PDT-treated NPC/HK1-tumors.	hypericin	62-71	matrix metallopeptidase 1	Homo sapiens	38-42
14767550-6	2004	To our knowledge, this is the first time that modulation of MMP-1 expression has been demonstrated as a photodynamic effect of hypericin in NPC cells.	hypericin	127-136	matrix metallopeptidase 1	Homo sapiens	60-65
14532982-3	2003	We have previously shown that hypericin-PDT induces tumor shrinkage and regression in the human nasopharyngeal cancer (NPC)/HK1 murine tumor model.	hypericin	30-39	hexokinase 1	Homo sapiens	124-127
14557269-0	2003	Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.	hypericin	74-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	17-33
14557269-0	2003	Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.	hypericin	74-83	mitogen-activated protein kinase 14	Homo sapiens	62-65
14557269-2	2003	We report that hypericin-mediated PDT of human cancer cells leads to up-regulation of the inducible cyclooxygenase-2 (COX-2) enzyme and the subsequent release of PGE2.	hypericin	15-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	100-116
14557269-2	2003	We report that hypericin-mediated PDT of human cancer cells leads to up-regulation of the inducible cyclooxygenase-2 (COX-2) enzyme and the subsequent release of PGE2.	hypericin	15-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	118-123
14678981-2	2003	We show in tumor cells that hypericin targets the heat shock protein (Hsp) 90 chaperone but not Hsp70 (Hsc70) to enhanced ubiquitinylation.	hypericin	28-37	heat shock protein 90 alpha family class A member 1	Homo sapiens	50-77
14532982-4	2003	In this extended study, we show by electron microscopy that subcutaneously implanted HK1 NPC cells from Balb/c nude mice perished by cell necrosis with hypericin-PDT treatment.	hypericin	152-161	hexokinase 1	Mus musculus	85-88
12101183-3	2002	Here we show that, in HeLa cells, photoactivated hypericin does not cause Bcl-2 degradation but induces Bcl-2 phosphorylation in a dose- and time-dependent manner.	hypericin	49-58	BCL2 apoptosis regulator	Homo sapiens	104-109
12403454-0	2002	Photobleaching of hypericin bound to human serum albumin, cultured adenocarcinoma cells and nude mice skin.	hypericin	18-27	albumin	Mus musculus	43-56
12101183-0	2002	Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis.	hypericin	90-99	BCL2 apoptosis regulator	Homo sapiens	19-24
12101183-0	2002	Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis.	hypericin	90-99	cyclin dependent kinase 1	Homo sapiens	111-115
12060853-4	2002	Incubation with hypericin, a natural photosensitizer increased IL-8 significantly but only in HK1 cells.	hypericin	16-25	C-X-C motif chemokine ligand 8	Homo sapiens	63-67
12060853-4	2002	Incubation with hypericin, a natural photosensitizer increased IL-8 significantly but only in HK1 cells.	hypericin	16-25	hexokinase 1	Homo sapiens	94-97
11956650-2	2002	Perylquinone photosensitizers such as Hypocrellin A (HA), Hypocrellin B (HB) and Hypericin (HY) induced activation of caspase-3 and apoptosis upon photoactivation.	hypericin	81-90	caspase 3	Homo sapiens	118-127
12622408-8	2002	Hypericin alone was able to induce short-time activation of NF-kappaB, which declined to basal levels after 24 h. Cell death was induced by hypericin at a concentration of 10 microM.	hypericin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	60-69
11857421-0	2002	Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model.	hypericin	26-35	replication timing regulatory factor 1	Mus musculus	81-86
11743662-0	2002	Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes.	hypericin	34-43	transferrin	Homo sapiens	0-11
11743662-5	2002	The aim of this study was to improve the specificity of hypericin for tumor cells using transferrin-conjugated PEG-liposomes.	hypericin	56-65	transferrin	Homo sapiens	88-99
11743662-12	2002	Targeting hypericin by transferrin-conjugated PEG-liposomes did not significantly favour the photocytotoxicity and the intracellular accumulation of hypericin, in comparison with non-targeted PEG-liposomes or free hypericin.	hypericin	10-19	transferrin	Homo sapiens	23-34
11743662-14	2002	Despite of their proven efficiency as a targeting carrier system, transferrin-conjugated PEG-liposomes seem less effective in targeting hypericin to tumor cells due to the amount of hypericin leaking out of the PEG-liposomes.	hypericin	136-145	transferrin	Homo sapiens	66-77
11743662-14	2002	Despite of their proven efficiency as a targeting carrier system, transferrin-conjugated PEG-liposomes seem less effective in targeting hypericin to tumor cells due to the amount of hypericin leaking out of the PEG-liposomes.	hypericin	182-191	transferrin	Homo sapiens	66-77
11852097-1	2002	Photosensitization of HEC1-B cells with a low concentration of hypericin and doses of light below 10 J/cm(2) caused cell death (apoptosis occurred mainly at doses between 2 and 5 J/cm(2), whereas necrosis prevailed above 6 J/cm(2)).	hypericin	63-72	NDC80 kinetochore complex component	Homo sapiens	22-26
12224088-1	2002	BACKGROUND AND OBJECTIVES: In the previous study, we have found a synergistic effect on the RIF-1 tumor cell killing when hypericin-mediated photodynamic therapy (PDT) was combined with hyperthermia.	hypericin	122-131	replication timing regulatory factor 1	Mus musculus	92-97
12622408-10	2002	In contrast, hypericin in low concentrations was able to partly prevent cell death induced by amyloid-beta-peptide (Abeta).	hypericin	13-22	amyloid beta precursor protein	Homo sapiens	116-121
11739235-5	2001	The present study characterized the response of P-gp to chronic and acute exposure of SJW and hypericin (HYP, a presumed active moiety within SJW) in an in vitro system.	hypericin	94-103	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
12224088-2	2002	The purpose of the present study was to investigate the antitumoral effect of hypericin-PDT in combination with hyperthermia in the RIF-1 mouse tumor model.	hypericin	78-87	replication timing regulatory factor 1	Mus musculus	132-137
12511190-2	2002	In the present work, we studied the effects of three inhibitors of crucial mechanisms responsible for intracellular pH (pHi) regulation on hypericin phototoxicity: N-ethylmaleimide (NEM), an inhibitor of H+-ATPase, 5"-(N,N-dimethyl)-amiloride (DMA), an inhibitor of Na+/H+ exchanger, and omeprazole (OME), an inhibitor of H+K+-ATPase.	hypericin	139-148	glucose-6-phosphate isomerase	Homo sapiens	120-123
11605021-0	2001	Induction of apoptosis by Hypericin through activation of caspase-3 in human carcinoma cells.	hypericin	26-35	caspase 3	Homo sapiens	58-67
12567741-9	2001	Hypericin has potential as a therapeutic drug for proliferative vitreoretinopathy(PVR), the inhibitory effect on PVR might be caused by blocking the PKC activity and inhibiting Ca2+ influx pathway.	hypericin	0-9	PVR cell adhesion molecule	Homo sapiens	82-85
12567741-9	2001	Hypericin has potential as a therapeutic drug for proliferative vitreoretinopathy(PVR), the inhibitory effect on PVR might be caused by blocking the PKC activity and inhibiting Ca2+ influx pathway.	hypericin	0-9	PVR cell adhesion molecule	Homo sapiens	113-116
11547546-0	2001	Different pathways mediate cytochrome c release after photodynamic therapy with hypericin.	hypericin	80-89	cytochrome c, somatic	Homo sapiens	27-39
11547546-1	2001	In this study we show that overexpression of Bcl-2 in PC60R1R2 cells reveals a caspase-dependent mechanism of cytochrome c release following photodynamic therapy (PDT) with hypericin.	hypericin	173-182	BCL2 apoptosis regulator	Homo sapiens	45-50
11547546-1	2001	In this study we show that overexpression of Bcl-2 in PC60R1R2 cells reveals a caspase-dependent mechanism of cytochrome c release following photodynamic therapy (PDT) with hypericin.	hypericin	173-182	cytochrome c, somatic	Homo sapiens	110-122
11547546-4	2001	Hypericin-induced mitochondrial depolarization coincided with cytochrome c release in PC60R1R2 cells while it precedes massive cytochrome c efflux in PC60R1R2/Bcl-2 cells.	hypericin	0-9	cytochrome c, somatic	Homo sapiens	62-74
11547546-4	2001	Hypericin-induced mitochondrial depolarization coincided with cytochrome c release in PC60R1R2 cells while it precedes massive cytochrome c efflux in PC60R1R2/Bcl-2 cells.	hypericin	0-9	cytochrome c, somatic	Homo sapiens	127-139
11547546-4	2001	Hypericin-induced mitochondrial depolarization coincided with cytochrome c release in PC60R1R2 cells while it precedes massive cytochrome c efflux in PC60R1R2/Bcl-2 cells.	hypericin	0-9	BCL2 apoptosis regulator	Homo sapiens	159-164
11410877-0	2001	Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model.	hypericin	50-59	replication timing regulatory factor 1	Mus musculus	130-135
11155494-7	2000	Like other working parties, we were only able to identify a weak inhibitory effect of the extract and the pure substance hypericin on the monoamine oxidases A and B.	hypericin	121-130	monoamine oxidase A	Rattus norvegicus	138-164
11724334-0	2001	Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.	hypericin	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-22
11724334-4	2001	In this study, we investigated the effects of hypericin on the activity of the c-erbB-2 oncoprotein and its downstream kinases.	hypericin	46-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-87
11724334-6	2001	We used ovarian SK-OV-3 cells as a model to determine whether hypericin-induced cell death was associated with inhibition of c-erbB-2 expression and activation.	hypericin	62-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-133
11724334-9	2001	Inhibition of expression of the c-erbB-2 protein was detected, using a monoclonal anti-erbB-2 antibody after 12-48 hrs of exposure to hypericin.	hypericin	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-40
11724334-9	2001	Inhibition of expression of the c-erbB-2 protein was detected, using a monoclonal anti-erbB-2 antibody after 12-48 hrs of exposure to hypericin.	hypericin	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-40
11724334-10	2001	Hypericin was found to inhibit autophosphorylation of the erbB-2 protein and downstream kinases such as MEK and ERK1/2.	hypericin	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	58-64
11724334-10	2001	Hypericin was found to inhibit autophosphorylation of the erbB-2 protein and downstream kinases such as MEK and ERK1/2.	hypericin	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	104-107
11724334-10	2001	Hypericin was found to inhibit autophosphorylation of the erbB-2 protein and downstream kinases such as MEK and ERK1/2.	hypericin	0-9	mitogen-activated protein kinase 3	Homo sapiens	112-118
11724334-11	2001	We also found up-regulation of p21WAF1 expression and down-regulation of Bcl-2 in hypericin treated cells.	hypericin	82-91	BCL2 apoptosis regulator	Homo sapiens	73-78
11724334-14	2001	From these results, we conclude that hypericin inhibits the growth of SK-OV-3 ovarian cancer cells, inhibits the autophosphorylation of c-erbB-2, induces apoptosis, and may inhibit invasion.	hypericin	37-46	erb-b2 receptor tyrosine kinase 2	Homo sapiens	136-144
11518063-3	2001	Hypericin showed the most potent binding inhibiton of all tested constituents to human CRF1 receptor with an IC50 value of 300 nM.	hypericin	0-9	corticotropin releasing hormone receptor 1	Homo sapiens	87-91
11518063-4	2001	Preliminary GTPgamma35S binding studies to CRF1 coupled G-protein indicated an antagonistic action for hypericin.	hypericin	103-112	corticotropin releasing hormone receptor 1	Homo sapiens	43-47
11332029-3	2001	Photosensitized damage to K562 leukemia cells from cis-di(4-sulfonatophenyl)diphenylporphine, hypericin and protoporphyrin IX was inhibited by GRP-carotenal under conditions where beta-apo-8"-carotenal, beta-carotene and crocetin were ineffective.	hypericin	94-103	gastrin releasing peptide	Homo sapiens	143-146
11277999-0	2001	Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8.	hypericin	0-9	TNF superfamily member 10	Homo sapiens	104-109
11277999-0	2001	Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8.	hypericin	0-9	caspase 8	Homo sapiens	129-138
10364831-0	1999	Hypericin as a non-antioxidant inhibitor of NF-kappa B.	hypericin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	44-54
10871299-6	2000	In addition, three other constituents, hypericin, quercetin, and chlorogenic acid, were tested for inhibitory activity toward the CYP enzymes.	hypericin	39-48	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133
10744649-4	2000	The findings suggest that the action of hypericin targets the effector CTL; however, apoptosis induced in murine L-cells with recombinant tumor necrosis factor (TNF)-alpha was also prevented by hypericin.	hypericin	40-49	tumor necrosis factor	Mus musculus	138-171
10744649-4	2000	The findings suggest that the action of hypericin targets the effector CTL; however, apoptosis induced in murine L-cells with recombinant tumor necrosis factor (TNF)-alpha was also prevented by hypericin.	hypericin	194-203	tumor necrosis factor	Mus musculus	138-171
10622714-1	1999	Hypericin (HY) is a powerful photo-inducer of apoptosis in Jurkat cells as measured by caspase-3 activation, cell shrinkage, phosphatidylserine (PS) exposure and the appearance of hypoploid DNA.	hypericin	0-9	caspase 3	Homo sapiens	87-96
10471290-0	1999	Targeted cross-linking of a molten globule form of acetylcholinesterase by the virucidal agent hypericin.	hypericin	95-104	acetylcholinesterase (Cartwright blood group)	Homo sapiens	51-71
10471290-4	1999	We here demonstrate that hypericin binds to a molten globule species generated from Torpedo acetylcholinesterase, but not to the corresponding native enzyme.	hypericin	25-34	acetylcholinesterase (Cartwright blood group)	Homo sapiens	92-112
10471290-7	1999	This agrees with our observation, using spin traps, that mainly singlet oxygen is produced by the complex of hypericin with the molten globule of acetylcholinesterase.	hypericin	109-118	acetylcholinesterase (Cartwright blood group)	Homo sapiens	146-166
11194175-5	2000	However, after 24 and 48 hours of illumination there is evident that hypericin in this concentration cleaved PARP (116 kDa) into two fragments (85 and 25 kDa).	hypericin	69-78	poly(ADP-ribose) polymerase 1	Homo sapiens	109-113
10871299-9	2000	Hypericin also demonstrated potent inhibition of several CYP activities.	hypericin	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	57-60
10969720-5	2000	Dillapiol, hypericin, and naringenin had the lowest IC50 values among the pure plant compounds at < 0.5 mM; dillapiol was the most potent inhibitor at 23.3 times the concentration of the positive CYP3A4 inhibitor ketoconazole.	hypericin	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	199-205
10799921-7	2000	Furthermore, addition of exogenous IL-10, but not IL-12, significantly increased the resistance of control inoculum-treated PBMCs to photoactivated 8-methoxypsoralen- and hypericin-induced apoptosis.	hypericin	171-180	interleukin 10	Homo sapiens	35-40
10378001-1	1999	Time-resolved fluorescence and absorption measurements are performed on hypericin complexed with human serum albumin, HSA (1:4, 1:1 and approximately 5:1 hypericin: HSA complexes).	hypericin	72-81	albumin	Homo sapiens	118-121
10378001-3	1999	Our results are consistent with the conclusions of previous studies indicating that hypericin binds to HSA by means of a specific hydrogen-bonded interaction between its carbonyl oxygen and the N1-H of the tryptophan residue in the IIA subdomain of HSA.	hypericin	84-93	albumin	Homo sapiens	103-106
10378001-3	1999	Our results are consistent with the conclusions of previous studies indicating that hypericin binds to HSA by means of a specific hydrogen-bonded interaction between its carbonyl oxygen and the N1-H of the tryptophan residue in the IIA subdomain of HSA.	hypericin	84-93	albumin	Homo sapiens	249-252
10378001-5	1999	A single-exponential rotational diffusion time of 31 ns is measured for hypericin bound to HSA, indicating that it is very rigidly held.	hypericin	72-81	albumin	Homo sapiens	91-94
10378001-6	1999	Energy transfer from the tryptophan residue of HSA to hypericin is very efficient and is characterized by a critical distance of 94 A, from which we estimate a time constant for energy transfer of approximately 3 x 10(-15) s. Although it is tightly bound to HSA, hypericin is still capable of executing excited-state intramolecular proton (or hydrogen atom) transfer in the approximately 5:1 complex, albeit to a lesser extent than when it is free in solution.	hypericin	54-63	albumin	Homo sapiens	47-50
10378001-6	1999	Energy transfer from the tryptophan residue of HSA to hypericin is very efficient and is characterized by a critical distance of 94 A, from which we estimate a time constant for energy transfer of approximately 3 x 10(-15) s. Although it is tightly bound to HSA, hypericin is still capable of executing excited-state intramolecular proton (or hydrogen atom) transfer in the approximately 5:1 complex, albeit to a lesser extent than when it is free in solution.	hypericin	54-63	albumin	Homo sapiens	258-261
10378001-6	1999	Energy transfer from the tryptophan residue of HSA to hypericin is very efficient and is characterized by a critical distance of 94 A, from which we estimate a time constant for energy transfer of approximately 3 x 10(-15) s. Although it is tightly bound to HSA, hypericin is still capable of executing excited-state intramolecular proton (or hydrogen atom) transfer in the approximately 5:1 complex, albeit to a lesser extent than when it is free in solution.	hypericin	263-272	albumin	Homo sapiens	47-50
10364831-2	1999	Here we show that micromolar concentrations of hypericin inhibited the PMA- and TNF-alpha-induced activation of NF-kappa B in HeLa and TC10 cells, respectively.	hypericin	47-56	tumor necrosis factor	Homo sapiens	80-89
10364831-2	1999	Here we show that micromolar concentrations of hypericin inhibited the PMA- and TNF-alpha-induced activation of NF-kappa B in HeLa and TC10 cells, respectively.	hypericin	47-56	nuclear factor kappa B subunit 1	Homo sapiens	112-122
10364831-3	1999	In contrast, NF-kappa B activated by H2O2 was not influenced by hypericin, indicating a pathway-specificity of hypericin.	hypericin	111-120	nuclear factor kappa B subunit 1	Homo sapiens	13-23
10364831-5	1999	The PMA/TNF-alpha-induced transcription of a reporter gene, which is under the control of the NF-kappa B-dependent IL-6 promoter, was strongly reduced by preincubation with hypericin.	hypericin	173-182	tumor necrosis factor	Homo sapiens	8-17
10364831-5	1999	The PMA/TNF-alpha-induced transcription of a reporter gene, which is under the control of the NF-kappa B-dependent IL-6 promoter, was strongly reduced by preincubation with hypericin.	hypericin	173-182	nuclear factor kappa B subunit 1	Homo sapiens	94-104
10085120-10	1999	These observations indicate that the JNK1 and p38 MAPK pathways play an important role in cellular resistance against PDT-induced apoptosis with hypericin.	hypericin	145-154	mitogen-activated protein kinase 8	Homo sapiens	37-41
10085120-0	1999	The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin.	hypericin	177-186	mitogen-activated protein kinase 8	Homo sapiens	22-45
10085120-10	1999	These observations indicate that the JNK1 and p38 MAPK pathways play an important role in cellular resistance against PDT-induced apoptosis with hypericin.	hypericin	145-154	mitogen-activated protein kinase 1	Homo sapiens	46-49
10085120-0	1999	The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin.	hypericin	177-186	mitogen-activated protein kinase 1	Homo sapiens	50-53
9865736-0	1998	Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria.	hypericin	33-42	hexokinase 1	Homo sapiens	109-119
10027308-9	1999	DTHe also differed from hypericin in effects exerted on the nuclear lamina, causing release of an 86-kDa lamin protein into the cytosol that was unique to DTHe.	hypericin	24-33	lamin A/C	Homo sapiens	68-73
9865736-11	1998	Hypericin also induced a dose- and light-dependent inhibition of [3H]thymidine uptake and induced apoptosis, as demonstrated by annexin V-FITC binding and cell morphology.	hypericin	0-9	annexin A5	Homo sapiens	128-137
9865736-13	1998	The multifaceted action of hypericin involves the alteration of mitochondria-bound hexokinase, initiating a cascade of events that converge to alter the energy metabolism of glioma cells and their survival.	hypericin	27-36	hexokinase 1	Homo sapiens	83-93
23194856-2	1996	The results show that hypericin inhibits the release of arachidonic acid (AA) from membrane phospholipids in calcium ionphore A23187-TPA stimulated human granulocytes in a dose-dependent manner (IC(50) 4 muM), but that calcium ionophore is not the only inducer.	hypericin	22-31	latexin	Homo sapiens	204-207
9862416-6	1998	Evidence is provided for the release of mitochondrial cytochrome c in the cytosol and for procaspase-3 activation in the hypericin-induced cell killing.	hypericin	121-130	caspase 3	Homo sapiens	90-102
9586812-2	1998	CuZnSOD and catalase activities peaked within 0.5 h following irradiation for nontoxic 0.5 microM hypericin and toxic 1.0 microM hypericin.	hypericin	98-107	superoxide dismutase 1, soluble	Mus musculus	0-7
9586812-2	1998	CuZnSOD and catalase activities peaked within 0.5 h following irradiation for nontoxic 0.5 microM hypericin and toxic 1.0 microM hypericin.	hypericin	129-138	superoxide dismutase 1, soluble	Mus musculus	0-7
9586812-7	1998	Glutathione reductase was inhibited immediately following irradiation with 1.0 microM hypericin, suggesting that an altered status of the glutathione pool contributed to cytotoxicity.	hypericin	86-95	glutathione reductase	Mus musculus	0-21
9586812-9	1998	Inhibition by hypericin in the dark was demonstrated for purified CuZnSOD, Se-dependent glutathione peroxidase, glutathione S-transferase, and glutathione reductase activities in vitro.	hypericin	14-23	superoxide dismutase 1, soluble	Mus musculus	66-73
9586812-9	1998	Inhibition by hypericin in the dark was demonstrated for purified CuZnSOD, Se-dependent glutathione peroxidase, glutathione S-transferase, and glutathione reductase activities in vitro.	hypericin	14-23	hematopoietic prostaglandin D synthase	Mus musculus	112-137
9586812-9	1998	Inhibition by hypericin in the dark was demonstrated for purified CuZnSOD, Se-dependent glutathione peroxidase, glutathione S-transferase, and glutathione reductase activities in vitro.	hypericin	14-23	glutathione reductase	Mus musculus	143-164
9570383-0	1997	Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor.	hypericin	76-85	proline rich transmembrane protein 2	Homo sapiens	96-112
9570383-1	1997	The effect of hypericin, an antiviral drug and a potent protein kinase C (PKC) inhibitor, on glioma cell invasion was investigated in vitro.	hypericin	14-23	proline rich transmembrane protein 2	Homo sapiens	56-72
9570383-1	1997	The effect of hypericin, an antiviral drug and a potent protein kinase C (PKC) inhibitor, on glioma cell invasion was investigated in vitro.	hypericin	14-23	proline rich transmembrane protein 2	Homo sapiens	74-77
9570383-3	1997	Furthermore, tamoxifen and staurosporine, both PKC inhibitors, also inhibited T98G cell invasion, suggesting that PKC may be the cellular target for hypericin-inhibited glioma cell migration.	hypericin	149-158	proline rich transmembrane protein 2	Homo sapiens	47-50
9570383-3	1997	Furthermore, tamoxifen and staurosporine, both PKC inhibitors, also inhibited T98G cell invasion, suggesting that PKC may be the cellular target for hypericin-inhibited glioma cell migration.	hypericin	149-158	proline rich transmembrane protein 2	Homo sapiens	114-117
9329022-0	1997	Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.	hypericin	0-9	BCL2 apoptosis regulator	Homo sapiens	95-100
23194856-5	1996	Hypericin also inhibits the production of IL-1alpha in LPS-stimulated human monocytes and activates NO production in isolated human leukocytes.	hypericin	0-9	interleukin 1 alpha	Homo sapiens	42-51
7487096-5	1995	NADPH oxidase activity in a cell-free system and TNF-alpha-induced tyrosyl phosphorylation of neutrophil proteins were also inhibited by hypericin in a concentration- and light-dependent manner.	hypericin	137-146	tumor necrosis factor	Homo sapiens	49-58
8626571-6	1996	Phosphorylation of Vif was stimulated by phorbol 12-myristate 13-acetate and inhibited by staurosporine and hypericin, a drug with potent anti-HIV activity.	hypericin	108-117	Vif	Human immunodeficiency virus 1	19-22
8646329-1	1996	Hypericin was determined using an RP C18 (3 microns) column 8.3 x 0.4 cm I.D.	hypericin	0-9	RNA polymerase II, I and III subunit H	Homo sapiens	34-40
8849331-1	1995	The effect of the anthranoids, anthralin and hypericin, on epidermal growth factor receptor (EGF-R) activation and their degree of specificity was examined.	hypericin	45-54	epidermal growth factor receptor	Homo sapiens	59-91
8849331-1	1995	The effect of the anthranoids, anthralin and hypericin, on epidermal growth factor receptor (EGF-R) activation and their degree of specificity was examined.	hypericin	45-54	epidermal growth factor receptor	Homo sapiens	93-98
8849331-2	1995	Hypericin, but not anthralin, was found to inhibit binding of [125I]-labelled epidermal growth factor (EGF) to HN5 squamous carcinoma cells that overexpress EGF-R.	hypericin	0-9	epidermal growth factor	Homo sapiens	78-101
8849331-2	1995	Hypericin, but not anthralin, was found to inhibit binding of [125I]-labelled epidermal growth factor (EGF) to HN5 squamous carcinoma cells that overexpress EGF-R.	hypericin	0-9	epidermal growth factor	Homo sapiens	103-106
8849331-2	1995	Hypericin, but not anthralin, was found to inhibit binding of [125I]-labelled epidermal growth factor (EGF) to HN5 squamous carcinoma cells that overexpress EGF-R.	hypericin	0-9	epidermal growth factor receptor	Homo sapiens	157-162
8849331-5	1995	Although anthralin and hypericin both inhibited the mitogenic effect of EGF in NR6/HER cells (IC50S = 100 nM and 10 microM, respectively), they also had comparable effects on DNA synthesis in response to acidic fibroblast growth factor (aFGF) and platelet-derived growth factor (PDGF).	hypericin	23-32	epidermal growth factor	Homo sapiens	72-75
8849331-7	1995	We conclude that, although anthralin and hypericin both inhibit EGF signalling, they do not act specifically on the EGF-R pathway.	hypericin	41-50	epidermal growth factor	Homo sapiens	64-67
7857510-0	1994	Inhibition of MAO and COMT by hypericum extracts and hypericin.	hypericin	53-62	catechol-O-methyltransferase	Homo sapiens	22-26
7786302-2	1995	Nanomolar concentrations of hypericin inhibit the protein tyrosine kinase activities (PTK) of the epidermal growth factor receptor and the insulin receptor, while being ineffective towards the cytosolic protein tyrosine kinases Lyn, Fgr, TPK-IIB and CSK.	hypericin	28-37	epidermal growth factor receptor	Homo sapiens	98-130
7786302-2	1995	Nanomolar concentrations of hypericin inhibit the protein tyrosine kinase activities (PTK) of the epidermal growth factor receptor and the insulin receptor, while being ineffective towards the cytosolic protein tyrosine kinases Lyn, Fgr, TPK-IIB and CSK.	hypericin	28-37	insulin receptor	Homo sapiens	139-155
7786302-2	1995	Nanomolar concentrations of hypericin inhibit the protein tyrosine kinase activities (PTK) of the epidermal growth factor receptor and the insulin receptor, while being ineffective towards the cytosolic protein tyrosine kinases Lyn, Fgr, TPK-IIB and CSK.	hypericin	28-37	FGR proto-oncogene, Src family tyrosine kinase	Homo sapiens	233-236
7786302-2	1995	Nanomolar concentrations of hypericin inhibit the protein tyrosine kinase activities (PTK) of the epidermal growth factor receptor and the insulin receptor, while being ineffective towards the cytosolic protein tyrosine kinases Lyn, Fgr, TPK-IIB and CSK.	hypericin	28-37	C-terminal Src kinase	Homo sapiens	250-253
8267642-1	1993	The naphthodianthrone hypericin produces a potent and irreversible inhibition of the epidermal growth factor (EGF) receptor tyrosine kinase activity.	hypericin	22-31	epidermal growth factor receptor	Homo sapiens	85-123
34361714-0	2021	Inhibitory Activity and Mechanism Investigation of Hypericin as a Novel alpha-Glucosidase Inhibitor.	hypericin	51-60	sucrase-isomaltase	Homo sapiens	72-89
34829932-7	2021	Destabilization of lysosomes, mitochondria and the Golgi apparatus led to an increase in lactate dehydrogenase activity, oxidative stress levels, LC3-II, and caspase-3, as well as a decrease of the PKCalpha and STAT3 protein levels in response to hypericin-PDT subcellular concentration in U87 MG cells.	hypericin	247-256	caspase 3	Homo sapiens	158-167
34829932-7	2021	Destabilization of lysosomes, mitochondria and the Golgi apparatus led to an increase in lactate dehydrogenase activity, oxidative stress levels, LC3-II, and caspase-3, as well as a decrease of the PKCalpha and STAT3 protein levels in response to hypericin-PDT subcellular concentration in U87 MG cells.	hypericin	247-256	protein kinase C alpha	Homo sapiens	198-206
34829932-7	2021	Destabilization of lysosomes, mitochondria and the Golgi apparatus led to an increase in lactate dehydrogenase activity, oxidative stress levels, LC3-II, and caspase-3, as well as a decrease of the PKCalpha and STAT3 protein levels in response to hypericin-PDT subcellular concentration in U87 MG cells.	hypericin	247-256	signal transducer and activator of transcription 3	Homo sapiens	211-216
34579929-0	2021	Surface tailored zein as a novel delivery system for hypericin: Application in photodynamic therapy.	hypericin	53-62	zein	Zea mays	17-21
34579929-3	2021	In this work, we report zein as a carrier for the natural photosensitizer hypericin in the PDT of hepatocellular carcinoma in vitro.	hypericin	74-83	zein	Zea mays	24-28
34579929-7	2021	The obtained results showed relatively smaller sizes and higher encapsulation of hypericin in the micellar zein than the nanoparticle-based formulations.	hypericin	81-90	zein	Zea mays	107-111
34579929-12	2021	Our investigations suggested that the surface-modified zein could be employed to enhance the delivery of the hydrophobic hypericin in PDT and pave the way for future in vivo and clinical applications in cancer treatment.	hypericin	121-130	zein	Zea mays	55-59
24264908-4	1990	However, hypericin is not sequestered either in the glands or elsewhere in the body ofChrysolina spp.	hypericin	9-18	histocompatibility minor 13	Homo sapiens	97-100
34655918-6	2022	Here, our aim was to extend our previous studies, with hypericin and cyanidin-3-O-glucoside, as potential inhibitors of the SARS-CoV-2 Mpro.	hypericin	55-64	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	135-139
34655918-8	2022	We also invoked PELE Monte Carlo simulations which indicate that both hypericin and cyanidin-3-O-glucoside preferentially interact with the Mpro active site and known allosteric sites.	hypericin	70-79	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	140-144
34655918-9	2022	For further validation, we performed an in vitro enzymatic activity assay that demonstrated that hypericin and cyanidin-3-O-glucoside inhibit Mpro activity in a dose-dependent manner at biologically relevant (muM) concentrations.	hypericin	97-106	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	142-146
34961797-3	2021	Molecular dynamics and PELE Monte Carlo simulations highlight favourable binding of hypericin and GRL-0617 to the naphthalene binding pocket of PLpro.	hypericin	84-93	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	144-149
34961797-4	2021	Although not potent as GRL-0617 (45.8 vs 1.6microM for protease activity, respectively), in vitro fluorogenic enzymatic assays with hypericin show concentration-dependent inhibition of both PLpro protease and deubiquitinating activities.	hypericin	132-141	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	190-195
34361714-2	2021	In this study, the inhibition of hypericin by alpha-glucosidase and its mechanism were firstly investigated using enzyme kinetics analysis, real-time interaction analysis between hypericin and alpha-glucosidase by surface plasmon resonance (SPR), and molecular docking simulation.	hypericin	33-42	sucrase-isomaltase	Homo sapiens	46-63
34361714-2	2021	In this study, the inhibition of hypericin by alpha-glucosidase and its mechanism were firstly investigated using enzyme kinetics analysis, real-time interaction analysis between hypericin and alpha-glucosidase by surface plasmon resonance (SPR), and molecular docking simulation.	hypericin	33-42	sucrase-isomaltase	Homo sapiens	193-210
34361714-2	2021	In this study, the inhibition of hypericin by alpha-glucosidase and its mechanism were firstly investigated using enzyme kinetics analysis, real-time interaction analysis between hypericin and alpha-glucosidase by surface plasmon resonance (SPR), and molecular docking simulation.	hypericin	179-188	sucrase-isomaltase	Homo sapiens	46-63
34361714-2	2021	In this study, the inhibition of hypericin by alpha-glucosidase and its mechanism were firstly investigated using enzyme kinetics analysis, real-time interaction analysis between hypericin and alpha-glucosidase by surface plasmon resonance (SPR), and molecular docking simulation.	hypericin	179-188	sucrase-isomaltase	Homo sapiens	193-210
34361714-3	2021	The results showed that hypericin was a high potential reversible and competitive alpha-glucosidase inhibitor, with a maximum half inhibitory concentration (IC50) of 4.66 +- 0.27 mg/L.	hypericin	24-33	sucrase-isomaltase	Homo sapiens	82-99
34361714-4	2021	The binding affinities of hypericin with alpha-glucosidase were assessed using an SPR detection system, which indicated that these were strong and fast, with balances dissociation constant (KD) values of 6.56 x 10-5 M and exhibited a slow dissociation reaction.	hypericin	26-35	sucrase-isomaltase	Homo sapiens	41-58
34361714-6	2021	In addition, hydrogen bonding occurred between hypericin and alpha-glucosidase amino acid residues Lys-156, Ser-157, Gly-160, Ser-240, His-280, Asp-242, and Asp-307.	hypericin	47-56	sucrase-isomaltase	Homo sapiens	61-78
34361714-8	2021	This research identified that hypericin, an anthracene ketone compound, could be a novel alpha-glucosidase inhibitor and further applied to the development of potential anti-diabetic drugs.	hypericin	30-39	sucrase-isomaltase	Homo sapiens	89-106
34356309-5	2021	In the present review, we provide evidence that different nutraceuticals, such as Hypericum perforatum (hypericin and hyperforin), flavonoids such as hesperidin, omega-3, and carnosine, can target TGF-beta1 signaling and increase TGF-beta1 production in the central nervous system as well as cognitive function.	hypericin	104-113	transforming growth factor beta 1	Homo sapiens	197-206
34356309-5	2021	In the present review, we provide evidence that different nutraceuticals, such as Hypericum perforatum (hypericin and hyperforin), flavonoids such as hesperidin, omega-3, and carnosine, can target TGF-beta1 signaling and increase TGF-beta1 production in the central nervous system as well as cognitive function.	hypericin	104-113	transforming growth factor beta 1	Homo sapiens	230-239
35532092-8	2022	MM-GBSA calculated the binding free energy uncovered that withanolide D, hypericin, and silymarin result in highly stable binding conformations in three different sites of the nucleocapsid protein.	hypericin	73-82	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	176-188
35398261-5	2022	METHODS: Preliminary studies confirmed that U87 cells (derived from a human grade 4 astrocytoma) could be killed by conventional PDT using the photosensitisers hypericin or mTHPC.	hypericin	160-169	small nucleolar RNA, C/D box 87	Homo sapiens	44-47
35398261-7	2022	Reagent doses and conditions were optimized and U87-luc cells incubated with hypericin or mTHPC with d-luciferin added to initiate bioluminescence activated PDT (bPDT).	hypericin	77-86	small nucleolar RNA, C/D box 87	Homo sapiens	48-51
34089613-0	2022	Hypericin-mediated photodynamic therapy enhances gemcitabine induced Capan-2 cell apoptosis via inhibiting NADPH level.	hypericin	0-9	2,4-dienoyl-CoA reductase 1	Homo sapiens	107-112
34089613-8	2022	Gem + HY inhibits the expression of Bcl-2 but stimulates Bax level, triggering caspase activation and PARP cleavage and thus promoted apoptosis of Capan-2 cells.	hypericin	6-8	BCL2 apoptosis regulator	Homo sapiens	36-41
34089613-8	2022	Gem + HY inhibits the expression of Bcl-2 but stimulates Bax level, triggering caspase activation and PARP cleavage and thus promoted apoptosis of Capan-2 cells.	hypericin	6-8	BCL2 associated X, apoptosis regulator	Homo sapiens	57-60
34089613-8	2022	Gem + HY inhibits the expression of Bcl-2 but stimulates Bax level, triggering caspase activation and PARP cleavage and thus promoted apoptosis of Capan-2 cells.	hypericin	6-8	collagen type XI alpha 2 chain	Homo sapiens	102-106
35633560-2	2022	Here, we investigated the antitumoral and antimigratory effects of hypericin (HYP) encapsulated on Pluronic F127 (F127/HYP) photodynamic therapy (PDT) against TNBC cell line MDA-MB-231 compared to a nontumorigenic human breast ductal cell line (MCF-10A).	hypericin	67-76	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	114-122
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	130-139	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	167-171
35101848-0	2022	The protective effect of hypericin on postpartum depression rat model by inhibiting the NLRP3 inflammasome activation and regulating glucocorticoid metabolism.	hypericin	25-34	NLR family, pyrin domain containing 3	Rattus norvegicus	88-93
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	39-48	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	104-108
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	130-139	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	230-234
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	39-48	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	167-171
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	187-196	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	104-108
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	39-48	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	230-234
35337106-11	2022	Enzyme inhibition assays revealed that hypericin, rosmarinic acid, isorhamnetin, and luteolin inhibited Mpro of SARS-CoV-2, while hypericin and isorhamnetin inhibited Mpro of SARS-CoV-1; hypericin showed inhibitory effects toward Mpro of MERS-CoV.	hypericin	187-196	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	230-234
35337106-14	2022	We demonstrated that hypericin represents a potential novel pan-anti-coronaviral agent by binding to and inhibiting Mpro of several human-pathogenic coronaviruses.	hypericin	21-30	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	116-120
35114918-0	2022	Substrate-dependent inhibition of hypericin on human carboxylesterase 2: implications for herb-drug combination.	hypericin	34-43	carboxylesterase 2	Homo sapiens	53-71
35222340-7	2022	Our results showed that, among the identified potential drugs with anti-SARS-CoV-2 properties, Hypericin, an important component of the Hypericum perforatum that presents antiviral and antitumoral properties, binds with high affinity to viral Mpro and RdRp.	hypericin	95-104	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	243-247
35222340-7	2022	Our results showed that, among the identified potential drugs with anti-SARS-CoV-2 properties, Hypericin, an important component of the Hypericum perforatum that presents antiviral and antitumoral properties, binds with high affinity to viral Mpro and RdRp.	hypericin	95-104	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	252-256
35114918-2	2022	Previous studies have shown that hypericin can strongly inhibit human cytochrome P450 (CYP) enzyme activities; however, its potential interactions that inhibit human carboxylesterases 2 (hCE2) were unclear.	hypericin	33-42	carboxylesterase 2	Homo sapiens	187-191
35114918-3	2022	PURPOSE: The study aimed to investigate the inhibition of hypericin on hCE2.	hypericin	58-67	carboxylesterase 2	Homo sapiens	71-75
35114918-4	2022	METHODS: The inhibition of hypericin on hCE2 was studied by using N-(2-butyl-1,3-dioxo-2,3-dihydro-1H-phenalen-6-yl)-2-chloroacetamide (NCEN).	hypericin	27-36	carboxylesterase 2	Homo sapiens	40-44
35114918-5	2022	The type of inhibition of hypericin on hCE2 and the corresponding inhibition constant (Ki) value were determined.	hypericin	26-35	carboxylesterase 2	Homo sapiens	39-43
35114918-6	2022	The inhibition of hypericin on hCE2 in living cells was discussed.	hypericin	18-27	carboxylesterase 2	Homo sapiens	31-35
35114918-7	2022	The herb-drug interactions (HDI) risk of hypericin and hCE2 in vivo was predicted by estimating the drug concentration-time curve (AUC) ratio of hypericin and hypericin free.	hypericin	145-154	carboxylesterase 2	Homo sapiens	55-59
35114918-7	2022	The herb-drug interactions (HDI) risk of hypericin and hCE2 in vivo was predicted by estimating the drug concentration-time curve (AUC) ratio of hypericin and hypericin free.	hypericin	159-168	carboxylesterase 2	Homo sapiens	55-59
35114918-8	2022	To understand the inhibition mechanism of hypericin on the activity of hCE2 in-depth, molecular docking was performed.	hypericin	42-51	carboxylesterase 2	Homo sapiens	71-75
35114918-12	2022	Moreover, hypericin distinctly suppressed hCE2 activity in living cells.	hypericin	10-19	carboxylesterase 2	Homo sapiens	42-46
35114918-13	2022	In addition, the AUC of hCE2 metabolic drugs with metabolic sites similar to NCEN was estimated to increase by up to 5%, in the presence of hypericin.	hypericin	140-149	carboxylesterase 2	Homo sapiens	24-28
35114918-15	2022	Further, molecular simulations indicated that hypericin could strongly interact with ASP98, PHE307, and ARG355 to form four hydrogen bonds within hCE2.	hypericin	46-55	carboxylesterase 2	Homo sapiens	146-150
35114918-16	2022	CONCLUSION: These findings are of considerable clinical significance to the combination of hypericin-containing herbs and drugs metabolized by hCE2.	hypericin	91-100	carboxylesterase 2	Homo sapiens	143-147